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Abstract
The role of adenosine monophosphate activated kinase in luteal progesterone
production
Elizabeth Compton Bowdridge
Prostaglandin F2 alpha (PGF2α) has in vivo luteolytic actions on the bovine corpus luteum
(CL). Although PGF2α is utilized extensively in livestock to synchronize estrus, its
actions in vitro are controversial and do not always result in a reduction in progesterone
(P4) secretion. The mechanism of action of PGF2α is thought to involve activation of the
phospholipase C-Ca2+ pathway. The luteolytic actions of PGF2α are mediated through an
elevation of cytosolic Ca2+ involving activation of protein kinase C (PKC). Expression of
PKC isozymes and calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2)
change as the CL develops to a mature stage. Either CAMKK2 directly affects
steroidogenesis or works indirectly through an intermediary step, such as adenosinemonophosphate kinase (AMPK), which is activated through CAMKK2 targeted
phosphorylation. Specifically, the hypothesis that activation of PGF2α receptor (FP) in
the mature CL involves AMPK was examined. Expression of mRNA encoding a
potential target AMPK for the action of CAMKK2, was increased in the mature versus
developing CL. Furthermore, activation of FP induced rapid phosphorylation of AMPK.
An AMPK-specific inhibitor, dorsomorphin dichloride (DM), eliminated effects of
PGF2α on secretion of P4, supporting the hypothesis that activation of the FP receptor in
mature CL involves participation of AMPK. Furthermore, in vitro two AMPK activators,
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and metformin, decreased
basal P4 secretion in mature but not in developing CL. Effect of FP activation on
cholesterol transport in the mature CL was investigated. Both serum and luteal P4
declined as soon as 2 hours after PGF2α administration, which was paralleled by a
decrease in protein concentration of low density lipoprotein receptor (LDLR). Human
mural granulosal cells are collected routinely when a patient is undergoing in vitro
fertilization (IVF) and are useful for studying granulosal lutein cells of the CL. Altering
intracellular calcium in these cells through an ionophore, A23187, increased basal P4
production. However, at high concentrations a calcium chelator, BAPTA, decreased P4
from mural granulosal cells. Infertility is a problem that affects more than 6.1 million
women and their partners across the United States. Causes of infertility range from
female related tubal factors such as blockage, endometriosis, diminished ovarian reserve,
to male related infertility due to abnormal sperm motility or morphology to unexplained
infertility. Primary infertility types, age, BMI, and pregnancy outcome influenced ability
of granulosal cells to increase P4 production when stimulated with human chorionic
gonadotropin (hCG). AICAR decreased basal P4 production in these cells, which is
similar to earlier observations in the mature bovine CL. Thus, AMPK appears to be a
distal target in the pathway responsible for mediating the actions of PGF2α. Directly
activating AMPK could lead to better estrous cycle manipulation in the cow, or
overcoming luteal insufficiency in women undergoing IVF.
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Chapter 1: Literature Review
Introduction
Follicles, composed of the oocyte, granulosal and thecal cells, are the functional unit of
the ovary. The somatic cells in the outermost vascular portion of the follicle include thecal and
myoepithelial cells. Myoepithelial cells aid in rupture of the follicle during ovulation by
increasing intrafollicular pressure through contraction. At least two populations of thecal cells
are recognized: theca interna and theca externa. The theca interna expresses luteinizing hormone
(LH) receptor and produces androstenedione, but does not contain aromatase, the enzyme needed
for conversion of androstendione to estrogen, which is expressed in granulosal cells (Hseuh et
al., 1984). The avascular component of the follicle is delimited by a basement membrane upon
which the other somatic cells of the follicle, the granulosal epithelial layer and the germ cell
reside. Two populations of granulosal cells have been identified: mural and cumulus granulosal
cells. Both populations of cells are organized as a stratified epithelium with the basal layer of
mural cells contacting the basement membrane adjacent to the thecal cells and the cumulus cells
surrounding the oocyte (Buccione et al., 1990). The 2-cell, 2-gonadotropin theory was first
suggested 50 years ago (Short, 1961). The theory is essential in understanding the role that these
two types of granulosal cells play in estrogen secretion from the growing follicle (Liu and Hsueh,
1986). In most mammalian species, formation of a follicular antrum, a fluid filled form of
extracellular matrix (ECM; Rogers and Rogers, 2010), divides these two populations of
granulosal cells. Presumably, the antrum is formed by an osmotic gradient that draws fluid from
the vasculature that is adjacent to the thecal cell population (Rogers and Rogers, 2010).
Granulosal cells produce both hyaluronan and versican, and these two molecules contribute to
cumulus cell expansion (Rogers and Rogers, 2010). After antrum formation, mural granulosal
1

cells express both FSH and LH receptor as well as 3β-HSD and P450 SCC (Zoller and Weisz,
1979) the expression of these two enzymes is more a luteal feature in these cells. Cumulus
granulosal cells remain with the oocyte after ovulation and respond to the ovulatory LH surge by
assembling another specialized ECM by a process known as cumulus expansion (Russell and
Salustri, 2006). This unique set of somatic cells possess an epithelial phenotype and are tightly
connected to one another via intercellular processes, known as gap junctions, which allow for
passage of small molecules that regulate signaling and metabolism by the oocyte (Russell and
Salustri, 2006). This subset of granulosal cells has a gene expression profile that is specific for
cumulus cell expansion, which distinguishes them from mural granulosal cells, which do not
undergo expansion. Once ovulation has occurred, mural granulosal cells lose their ability to
proliferate, undergo epithelial-mesenchyme transition and differentiate into the large luteal cells
(LLC) of the corpus luteum (CL), which secrete high concentrations of basal progesterone
(Chaffkin et al., 1992). Theca cells become small luteal cells (SLC) once luteinization has
occurred. In the primate, the granulosal and thecal cells remain as two distinct populations and
are separated by the remnants of the follicular basement membrane (Guraya, 1971). In contrast,
the basement membrane separating these two cell populations is degraded, and thecal cells
invade the granulosa to form a heterogeneous mixture of cells in the CL of nonprimate species
(Niswender, 2000).

Development of the bovine corpus luteum
Neovascularization
The CL is a transient endocrine organ that begins to form immediately after ovulation and
requires extensive neovascularization to ensure both structural and functional development.
During the first eight to ten days of growth, the CL doubles in size and cell number every 60-70
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hours (Reynolds et al., 1994). This rate of growth is comparable to the fastest growing tumors,
yet, unlike tumors, cell proliferation in the CL is self-limiting and tightly regulated (Reynolds et
al., 1994). Ovulated follicular tissues of approximately 40 mg grow to 600-700 mg of CL tissue
within a few days (Reynolds, 2000). This growth can be attributed to hyperplasia of SLC,
fibroblasts, and endothelial cells, as well as hypertrophy LLCs without hyperplasia in the ovine
CL (Farin et al., 1986). However, in vitro both hypertrophy and hyperplasia occur in bovine
luteal steroidogenic cells as measured by cell cycle (cyclin D2 and E1) and cell proliferation
(Ki-67) genes (Yoshioka et al., 2013). To support such extensive cell growth, angiogenesis
occurs rapidly and reaches a maximum 2 to 3 days after ovulation (Reynolds, 2000). This
change is reflected by the fact that approximately 50-85% of the luteal cell proliferation occurs
in the microvasculature unit, and endothelial cells and pericytes make up over half of the cell
population in the mature CL (Reynolds et al., 1994). Increased vascularization enables the CL to
receive more blood flow per unit of tissue than any other mature organ in the body (Reynolds,
2000). Most membranes of luteal cells are either adjacent to capillaries or adjacent to the
interstitial space that is in close proximity to capillaries (Dharmarajan et al., 1985). Inadequate
or subfunctional luteal development is known to occur in cattle (Redmer & Reynolds, 1996) and
in humans (Reynolds et al., 2000) and is associated with reduced vascularization in both cases.
Several angiogenic factors contribute to the vascularization of the bovine CL. Two key
mediators in neovascularization are fibroblast growth factor 2 (FGF2) and vascular endothelial
growth factor (VEGF) A (Robinson et al., 2009). Both VEGF and its receptors VEGFR1 and
VEGFR2 mRNA are expressed in the bovine CL and endothelial cells (Berisha et al., 2000).
Additionally, VEGF is a mitogen for endothelial cells, and its expression is induced by the
preovulatory LH surge (Garrido et. al, 1993). In the cow, FGF2 protein synthesis occurs in
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endothelial cells and pericytes of the thecal layer occur prior to the LH surge and in the
luteinizing granulosa mainly after ovulation (Berisha et al., 2006). After a few days FGF2 was
absent from all steroidogenic cells but reappeared in endothelial cells (Berisha et al., 2006).
Both endothelial cells (Robinson et al., 2008) and pericytes (Robinson et al., 2007) are targets for
multiple angiogenic factors. Pericytes appear to play a dual role in neovascularization. First
they act as a guide for the outgrowth of endothelial cells, and secondly they help stabilize newly
formed vessels (Robinson et al., 2009). Changes in mRNA and protein expression in FGF2 that
occur after the LH surge imply that FGF2 is crucial for the follicle-luteal transition in cattle
(Robinson et al., 2007). The LH surge had no effect on VEGF concentrations, so VEGF is
thought to play a constitutive, but essential, role in the development of luteal vasculature
(Robinson et al., 2007). Both factors and their receptors are expressed at higher concentrations
in the developing bovine CL and decrease significantly in the maintenance to regressing CL
(Schams et al., 1994; Berisha et al., 2000).
Small and large luteal cells
Two morphologically distinct steroidogenic cells types comprise CL of cattle, sheep and
many other mammalian species (Niswender and Nett, 1994). Small luteal cells
(18-20 µm) are derived from the thecal cells of the follicle, contain receptor for luteinizing
hormone (LH), respond to LH by producing cAMP and increasing secretion of progesterone, and
usually contain multiple lipid droplets (Niswender, 2002). The number of SLC increased
four-fold from day 4 to day 8 in the estrous cycle of the ewe, but these cells maintained a
constant volume (Farin et al., 1986). Large luteal cells (25-40 µm) originate from granulosal
cells, secrete high basal concentrations of progesterone, and have receptors for both LH and
PGF2α (Niswender, 2002). Numbers of LLC did not change throughout the estrous cycle of the
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ewe but volume and diameter increased until day 16 of the cycle (Farin et al., 1986). Basal
secretion of progesterone differs between these two luteal cell types with LLC producing 2-40
times more progesterone than SLC (Niswender et al., 2000). Both LLC and SLC differ in their
response when stimulated with hormones and/or intracellular mediators. Physiological
concentrations of LH increased secretion of progesterone from bovine SLC but not LLC in vitro
(Alila et al., 1998). Steroidogenic cells in the CL synthesize large amounts of progesterone.
Increased synthesis of progesterone occurs as the CL develops and is maintained if a pregnancy
is established, or is abolished due to CL regression.
Progesterone production
All steroids, including progesterone, are derived from cholesterol, which can come from
the plasma membrane, cellular stores (lipid droplets), lipoproteins (low density lipoproteins
[LDL] and high density lipoproteins [HDL]), and de novo synthesis (Hu et al., 2010). Each LDL
particle contains approximately 2500 cholesterol molecules, which makes this pathway very
efficient for progesterone production. Uptake of LDL by luteal cells occurs by receptormediated endocytosis (Hu et al., 2010). During this process, LDL binds to its plasma membrane
(PM) bound receptor, which then translocates to specialized regions of the PM called coated pits
to invaginate and pinch off to form clathrin-coated vesicles (Hu et al., 2010). These vesicles
rapidly fuse with lysosomes where the protein of the LDL is hydrolyzed to amino acids and
cholesteryl esters are hydrolyzed by a lysosomal acid lipase (Brown and Goldstein, 1979). The
LDL-receptor complex rapidly dissociates with the full intact LDL-receptor being sorted and
returned to the PM. The resulting cholesterol from the LDL particle can be released and
transported to the mitochondria for steroid hormone synthesis (Hu et al., 2010) or undergo
esterification by A:cholesterol acyltransferase 1 (ACAT1). Additionally, ACAT1 is responsible
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for esterification of de novo synthesized cholesterol. Cholesterol esters are stored in lipid
droplets, which have been shown to be hormonally regulated in steroidogenic cells of the
adrenal, ovary and testis (Behrman and Greep, 1972; Hu et al., 2010).
The HDL is taken up by the cell by binding to the plasma membrane-bound HDL binding
protein (Lestavel and Fruchart, 1994), and cholesterol is mobilized into the cell by an undefined
mechanism. Free cholesterol is transported to the mitochondria along the cytoskeletal network
and by sterol carrier proteins where it is then transported from the outer to inner mitochondrial
membrane by steroidogenic acute regulatory protein (StAR) (Niswender, 2002). Cholesterol is
converted to pregnenolone by an inner mitochondrial enzyme, cytochrome P450 side chain
cleavage (P450scc). Pregnenolone travels out of the mitochondria and is converted to
progesterone by the smooth endoplasmic reticulum enzyme 3β-hydroxysteroid dehydrogenase
(3β-HSD) (Niswender, 2002). Additionally, peripheral-type benzodiazepine receptors (PBR)
may play a role in cholesterol transport as it is moved from the outer to inner mitochondrial
membranes (Niswender, 2002). Targeted deletion of the PBR from Leydig cells drastically
reduced steroid secretion, and reintroduction of PBR allowed steroid secretion to be restored
(Papadopoulos et al., 1997). Additionally, phosphorylation of PBR by protein kinase A (PKA)
enhanced cholesterol transport (Papadopoulos et al., 1997). It is possible that PBR works as a
cholesterol channel.
Luteinization of human mural granulosal cells
During follicular development granulosal cells primarily secrete estrogen (E2), but as
ovulation approaches they begin to produce progesterone (P4). During the preovulatory period
E2 secretion is drastically reduced, and granulosal cells begin to synthesize P4 (McNatty et al.,
1979). Additionally, these cells undergo loss of aromatase and mitotic activity (Robertson and
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Baker, 1969; Friedrich et al., 1975). Interestingly, P4 receptors (PGR) cannot be detected with
immunohistochemical analysis in human granulosal cells at any follicular stage but are detected
readily in human luteal tissue (Suzuki et al., 1994). This finding supports the hypothesis that LH
induces PGR expression (Hild-Petito et al., 1988).
Human granulosal cells recovered during oocyte retrieval in patients undergoing in vitro
fertilization have been shown to luteinize in culture and, therefore, have been used as a model to
study granulosal lutein cells of the CL (Stewart and Vandevoort, 1997). This model has several
advantages: no collagenases or other proteolytic enzymes that may influence hormone secretions
are needed for cell isolation; unlike ovarian cell line cultures, primary granulosal cell cultures
retain their ability to produce and respond to steroid hormones; and serum-free media can be
used to examine circulating hormones or serum-derived factors (Hsueh et al., 1984). This model
has limitations: absence of vascularization and the influence of angiogenic factors; inability of
other follicular cell types such as theca interna or oocyte-cumulus cells to influence granulosal
cell differentiation (Hsueh et al., 1984); and representative of only one stage of development of
the CL (which has not been clearly defined) and do not take into account the heterogeneity of a
granulosal cell population or the fertility status of the patient from which they were isolated.

Luteotropic versus luteolytic signals
Luteotropic hormones
Luteotropic hormones support the growth and/or function of the CL. Luteinizing
hormone (LH), growth hormone (GH), prolactin, insulin-like growth factor 1 (IGF-1),
prostaglandin (PG) E2 (PGE2) and prostacyclin (PGI2) are all luteotropic hormones. In order to
increase P4 LH acts on the SLC of most species and the LLC in pregnant and pseudopregnant
rats as well as nonhuman primates (Hild-Petito et al., 1989; Niswender et al., 2000). Most
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luteotropic hormones work by initiating the same intracellular mediator cascade. For example in
bovine luteal tissue or cells, LH binds to its G-protein-coupled receptor in SLC and activates
adenylate cyclase, which increases concentrations of cyclic adenosine monophosphate (cAMP)
and activates PKA (Hoyer et al., 1984). Increase in P4 is achieved through increased transport of
cholesterol to the P-450 SCC enzyme complex to the mitochondria (Wiltbank et al., 1993). The
LLC also express LH receptor but secrete more basal P4 than SLC, so an increase in response to
LH may be due to constitutively expressed PKA (Hoyer et al., 1984).
Luteolytic hormones
Luteolytic hormones promote luteal regression. In many species, including cattle, PGF2α
is the primary uterine factor responsible for functional and structural luteolysis (McCracken,
1971). Additionally, oxytocin and luteal PGF2α play roles in luteolysis. Increases in protein
kinase C (PKC) enzyme activity and intracellular calcium mediate the anti-steroidogenic effects
of PGF2α (Niswender et al., 2000). In fact, PGF2α-induced accumulation of extracellular
calcium in the cytosolic compartment enhances PKC enzyme activity (Niswender, 2000).
Metabolism and actions of intraluteal PGs, including but not limited to PGF2α, affect the
lifespan of the CL. Actions of luteal-derived PGF2α are likely mediated by the G-protein coupled
plasma membrane receptor, FP, that uterine PGF2α acts on (Wiltbank and Ottobre, 2003).
Expression of FP receptor mRNA is present at 100-fold greater concentrations in the CL than in
any other tissue, EP3 receptor is also expressed (Anderson et al., 2001). Koybayashi et al.
(2001) found that developing bovine CL (day 3) produce more PGF2α than mid phase CL (days
4-6). In agreement with those results, luteal concentrations of cyclooxygenase-2 (COX-2)
mRNA were greater in the developing than mature to regressing CL. Additionally, PGF2α
increased the availability of arachidonic acid (AA) and COX-2 activity, both essential for PG
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production in the CL (Niswender et al., 2000). This evidence supports the ability of PGF2α to
regulate its own production in the CL. However, a temporal relationship exists in the ratio of
luteotropic (PGI2) and luteolytic (PGF2α) PGs throughout the estrous cycle (Milvae and Hansel,
1983). Luteal PGs are stimulated by cytokines such as INFγ (Fairchild and Pate, 1991) and
TNFα (Benyo and Pate, 1992) but suppressed by high intraluteal concentrations of progesterone
(Pate, 1988). Although uterine-derived PGF2α is the main luteolytic factor in ruminants, other
PGs appear to play a role in determining the lifespan of the CL.
Luteal regression is not mediated by uterine PGF2α in primates (Beling, 1970). Infusion
of PGF2α directly into the CL reduced P4 and caused premature menses in monkeys (Auletta et
al., 1984). It has been suggested that luteal-derived PGF2α acts in a paracrine and/or autocrine
manner to induce luteal regression (Auletta and Flint, 1988). Despite this evidence, the source
and actions of PGF2α in the primate still remain controversial.
Oxytocin is secreted mainly by the posterior pituitary during and after parturition and
lactation in order for milk letdown to occur, but also it is an important factor during luteal
regression. Flint and Sheldrick (1982) showed that a rapid increase of ovarian oxytocin was
elicited within five minutes of administering a PGF2α analogue (Estrumate®, 125 µg i.m.). In
part due to this finding, McCracken et al. in 1996 suggested that the initiating factor for
luteolysis is stimulation of posterior pituitary oxytocin by E2 or the removal of P4 (McCracken et
al., 1996), which in turn stimulate secretion of uterine PGF2α (Fairclough et al., 1980). This
cascade leads to a positive feedback loop that causes the release of luteal oxytocin as well as
luteal and more uterine PGF2α (Silvia et al., 1991) leading to luteal regression. One explanation
for the time between pulses of naturally occurring uterine PGF2α is refractoriness of the uterus to
oxytocin. However, depletion of oxytocin or its receptors in the bovine CL did not delay
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luteolysis (Kotwica and Skarzynksi, 1999), implying that it is not critical for luteal regression.
The role of oxytocin in luteal regression remain controversial.

Signals for maintenance of corpora lutea
During gestation, maternal recognition of pregnancy must occur so that P4 synthesis and
secretion continue uninterrupted. Considerable variation exists among species, but, in general,
the conceptus secretes factors that are anti-luteolytic (anti-PGF2α) or luteotropic (Roberts et al.,
1996) to maintain the CL and P4 secretion. In the case of the human, [human] chorionic
gonadotropin (hCG) is secreted by the trophoblastic cells of the implanting embryo (Hearn et al.,
1991) and binds to the LH receptors in the CL to increase P4 secretion as well to protect the CL
from PGF2α (Patton and Stouffer, 1991). In contrast, in the cow, secretion of the protein
interferon tau (IFτ) by the trophectoderm of the elongating blastocyst has been postulated to
suppress the pulsatile release of PGF2α from the uterus (Roberts et al., 1996).
During a non-fertile luteal phase, luteotropic signals allow the CL to increase in size and
ability to secrete P4 (Niswender et al., 2000). However, if a pregnancy is not established, the CL
must regress in order for another follicle to grow, ovulate, and a new cycle begin. As mentioned
earlier, uterine PGF2α is the luteolytic signal in ruminants. In the cow, both large and small
luteal cells are capable of responding to PGF2α with an increase in intracellular Ca+2 (Choudhary
et al., 2004). The binding of PGF2α to its receptor in these luteal cells activates two pathways
that affect steroidogenesis in the CL. The first is activation of PKC, which directly inhibits
progesterone production (Niswender, 2002). Additionally, increases in free intracellular Ca+2
lead to apoptosis and cell death (Wiltbank et al., 1989). In primates, the role of PGF2α is
controversial but may play a role when it is of ovarian origin. Due to these actions PGF2α is
utilized extensively in livestock species to synchronize estrus. However, the bovine CL is
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resistant to luteal regression by exogenous PGF2α before day 5 (D 5) of the estrous cycle.
Estrous synchronization protocols
The discovery of PGF2α as the luteolysin in ruminant species led to an explosion of
synchronization protocols specifically in dairy cattle (Pursley et al. 1995). Synchronizing estrus
with exogenous PGF2α allowed for more easily detecting estrus in large herds as well as more
efficient artificial insemination (AI) programs (Stevenson and Pursley, 1994). Originally, PGF2α
was given twice, 11 days apart (Lucy et al., 1986). However, it was found that while 60% of
cows responded to the first PGF2α injection by CL regression only 72% responded to the second
injection when all animals should have had CL older than 5 days (Lucy et al., 1986). Due to
variabilty in time to estrus and low conception rates for fixed time AI, GnRH was incorporated
into estrous synchronization protocols in order to initiate a new follicular wave with a dominant
follicle prior to PGF2α and to more tightly synchronize ovulation 24 hours before breeding
(Pursley et al., 1995).
Responsiveness of corpora lutea to PGF2α
The ability of the CL to respond to the luteolytic actions of PGF2α increases with
maturation in cattle. The developing CL (days 1-5) will not regress if a single administration of
PGF2α is given, but in the mature CL (days 6-15), the same dose of exogenous PGF2α, will
induce regression, and the cow will come into estrus within 48-72 hours (Rowson, Tervit and
Brand, 1972; Inskeep, 1973). However, differences in response to PGF2α have been noted across
timespans during the mature phase of the CL. In 1984, Tanabe and Hann administered a single
injection of PGF2α on days 7, 11, or 15 of the estrous cycle in heifers and found that the
percentage of heifers exhibiting synchronized estrus at 80 hours afer PGF2α tended to increase
with stage of estrous cycle (day 7-86%, day 11-90%, and day 15-98%). This area of research has
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been under intensive investigation for many years, but the mechanism for the developmental
difference is still not understood. However, lack of receptors (Wiltbank, 1995; Wright et al.,
2014) or the ability of PGF2α to produce physiological responses (Tsai and Wiltbank, 1998; Sen
et al., 2005) do not explain this difference in the developing CL.
Normal versus induced corpora lutea
There is evidence that a CL formed after a spontaneous ovulation is characteristically
different than one formed when the previous CL is regressed by pharmaceutical methods. In a
study by Keisler and Keisler in 1989, CL that were induced in the absence of an existing CL
were short-lived whereas CL that were induced during the luteal phase of the estrous cycle did
not affect lifespan of spontaneous CL. However, in Brahman cattle, no difference in CL weight,
progesterone content, or number of LH receptors were found between spontaneous and induced
CL (Hansen et al., 1987). .
In multiple species, PGF2α elicits both inhibitory and stimulatory responses to P4 in luteal
cells in vitro. Most investigators used a non-physiological dose of PGF2α when treating luteal
cells in vitro. The fact that PGF2α at high concentration is able to activate the PGE2 receptor
(Rao, 1974) could, in part, explain increases in progesterone production. Additionally, the entire
population of cells that would normally be present in addition to luteinized granulosal cells are
not present in all in vitro experiments. The inhibitory action of PGF2α on human luteinized
granulosal cells may be enhanced by the presence of endothelial and/or immune cell types
(Liptak et al., 2005).

Structural and functional regression of corpora lutea
Structural versus functional
Through decades of luteal physiology research, luteal regression has come to be defined
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as either structural or functional (Bowen-Shauver and Telleria, 2003). Functional regression is
defined as the cessation of P4 production, whereas structural regression refers to a decrease in
weight and size of the CL (Goyeneche et al., 2002) and then disappearance of the structure on
the ovary (Bowen-Shauver and Telleria, 2003). Progress has been made in separating these two
events in vivo, as well as distinguishing between the two in the literature. However, it is
important that these terms are defined in the context of both the species and the reproductive
stage being studied (Davis and Rueda, 2002).
Signs of functional regression occur prior to structural regression; presumably the loss of
P4 production by the CL ultimately leads to its morphological changes and ultimately structural
regression. Initial changes seen in serum P4 are not due to loss of steroidogenic luteal cells,
because numbers of large luteal cells do not decrease until after a dramatic decrease in P4
(Braden et al., 1988). Therefore, a decrease in blood flow to the CL and decreased steroidogenic
capacity of luteal cells is one possible explanation for this decrease in P4. However, a decrease
in P4 prior to a decrease in luteal blood flow has been seen in rodents (Behrman et al., 1979)
rabbits (Keyes et al., 1983) and domestic species (Ginther et al., 2007). Studying spontaneous
luteolysis has proven to be difficult because timing, duration and number of pulses of uterine
PGF2α differ among individuals. Decreased mRNA and protein of enzymes (3β-HSD, StAR,
etc.) that contribute to luteal regression also are expressed at inconsistent times, which makes
finding significant changes within a group of animals difficult due to the variation. Due to this
fact, researchers have focused on subsequent changes in these key factors after administration of
PGF2α.
Structural regression occurs due to a series of physiological changes that result in distinct
morphological changes in the CL. One such event that contributes greatly to the demise of the
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CL is apoptosis, which is promoted by PGF2α (Sawyer, et al., 1990). Apoptosis, also known as
programmed cell death, is defined as an active, energy dependent process by which nonessential
populations of cells are removed by other cells from tissue (Kerr et al., 1972), a mechanism that
allows for control of cell numbers and tissue size. Apoptosis in endocrine tissues commonly
occurs after the tropic hormone is removed or a negative stimulus is activated. Cells shrink, and
fragments of both nuclear and cytoplasmic origin appear (Kerr et al., 1972). Apoptosis is
categorized into the intrinsic and extrinsic signaling cascade. The intrinsic pathway is activated
by apoptotic signals that originate within the cell in response to insults such as drugs, radiation,
or growth factor withdrawal. As a result, a change in mitochondrial permeability occurs through
modifications in the ratio of pro- to anti-apoptotic Bcl-2 family members (Adams and Cory,
1998). Alternatively, the extrinsic pathway is activated by extracellular signals, such as Fas, or
tumor necrosis factor alpha (TNF-α), that bind with cell surface receptors to inititate cell death
(Nagata, 1997). Caspases, a family of intracelluar proteases, are activated by both pathways and
cleave multiple cellular components that contribute to the typical morphological appearance in
apoptotic cells (Martin and Green, 1995). These fragments, known as apoptotic bodies, are
targets for macrophages and other immune cells.
Specifically, the proportion of steroidogenic luteal cells in the CL of ewes decreased
within 24 hours of PGF2α treatment during the maintenance phase (Braden et al., 1998). Both the
number and size of LLCs decreased, and this was followed by a decrease in the number of SLC
(Braden et al., 1998). Morphological changes in the steroidogenic cell population of the CL do
not become visible until 24-36 hours post PGF2α (Sawyer et al., 1990), yet their ability to
produce P4 has already been compromised. This indicates that the structural changes in the CL
are a consequence of reduced P4 production and not vice versa. However, it could indicate that
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functional regression is regulated by a different mechanism than apoptosis, such as autophagy.
Indeed, autophagy has been shown to play a role in structural regression in human and
rats. Autophagy is an intracellular bulk degradation system in which portions of cytoplasm are
enveloped into autophagosomes that then undergo maturation and fusion with lysosomes for
degradation (Klionsky and Emr, 2000). The apperance of cytoplasmic vacuoles, prominent
lysosomes, and the accumulation of lipfucsin pigment without any changes in nuclear
morphology in the regressing primate CL strongly indicate that autophagy induces or at least
plays a part in the death of steroidogenic luteal cells (Morales et al., 2000). Additionally,
autophagy has been shown to play a role in luteal regression in the rat by accumulation of
autophagosomes, which then induce apoptotic cell death in luteal cells (Choi et al., 2011).
Autophagy is promoted by adenosine monophosphate activated protein kinase (AMPK; Kim et
al., 2011). The role autophagy plays in bovine luteal regression has yet to be examined.
However, AMPK reduced P4 production in murine, galline and bovine granulosal cells (Tosca et
al., 2005; Tosca et al., 2006; Tosca et al., 2007), which will be discussed at greater length later in
this review. The link between AMPK and autophagy induction in bovine luteal tissue has not
been determined.
Factors involved in regression
Luteal blood flow
Changes in luteal blood flow have been proposed to be one of the main mechanisms by
which PGF2α exerts its luteolytic actions (Nett et al., 1976; Knickerbocker, 1988). In ewes,
PGF2α reduces blood flow to the CL concomitantly with decreased secretion of P4 (Nett et al.,
1976). Color Doppler ultrasound is a non-invasive and useful technique to examine blood flow
within the CL during its development (Acosta et al., 2003) and demise (Acosta et al., 2002). On

15

days 16-18 of the estrous cycle in cattle, during spontaneous luteolysis, an increase in blood flow
surrounding the CL was observed followed by decreased plasma P4 the next day (Shirasuna et
al., 2004; Miyamoto et al., 2005). An acute increase in blood flow (0.5 to 2 hours) also was seen
during PGF2α-induced luteolysis in mature (day 10) but not developing (day 4) bovine CL
(Acosta et al., 2002). This increase was followed by a decrease in plasma P4 at 0.5 hours and
blood flow at 8 hours (Acosta et al., 2002). Expression of vasoactive factors must increase in
order to mediate this increase in blood flow. One such factor, nitric oxide (NO), a vasodilator,
was proposed to be stimulated by PGF2α (Yamamoto et al., 2004). Indeed, in a different tissue, it
has been postulated that uterine PGF2α induces NO production from large arterioles to acutely
increase luteal blood flow and initiate luteolysis (Miyamoto et al., 2005). However, other
investigators were unable to find an increase in luteal blood flow at the initiation of luteolysis
(Ginther et al., 2007). In fact, a decrease in blood flow was not observed until the day after P4
decreased (Ginther et al., 2007).
Protective effect of progesterone
Luteal P4 has been shown to exert protective effects on CL as a luteotropin by increasing
the number of LH receptors in the early CL (Rothchild, 1981) and through anti-apoptotic activity
(Rueda et al., 1997). Direct supplementation of P4 to dispersed mature bovine luteal cells
initiated a decrease in prostacyclin and PGF2α synthesis (Pate, 1988), which indicates that P4
action could also be anti-luteolytic. This evidence shows that P4 can protect the lifespan of the
CL by blocking a decrease P4 production, reducing cell death, and preventing luteolytic factors
such as PGF2α from regressing the CL. The P4 receptor, PR, is present in LLC and some SLC,
but not endothelial cells (Rueda et al., 2000), and it was further delineated that two isoforms of
PR, PR-A and PR-B, are expressed in the bovine CL (Kotwica et al., 2004). Protein synthesis of
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these classical genomic receptors changes throughout the estrous cycle and pregnancy with the
highest concentrations found at days 5-10 of the cycle and no expression in the regressing CL
(Kotwica et al., 2004). Actions of P4 could be exerted through the genomic receptor; however,
these effects could be mediated by the glucocorticoid receptor (Sugino et al., 1997) or through
the non-genomic plasma membrane bound PR (Peluso, 1997).
Pulsatile uterine PGF2α
Prostaglandin F2α is released in a series of pulses from the non-pregnant uterus in order
to regress the bovine CL (Niswender, 2002). Uterine release of PGF2α is transferred to the ovary
through the utero-ovarian vein via a counter current exchange mechanism (McCracken et al.,
1972). This helps ensure that PGF2α is not enzymatically inactivated in the lungs by PG
dehydrogenase (PGHD) (Piper et al., 1970). Transport of PGs through plasma membranes is
poorly understand, but prostaglandin transporter (PGT) mediates the efflux and influx of PGF2α
(Schuster, 1998). Recently Lee et al. (2013) showed PGT protein was required for pulsatile
release of PGF2α from the endometrium and to maintain a functional CL in sheep. Number and
frequency of pulses vary considerably during natural ruminant luteal regression but
approximately 5 distinct pulses, each around 4-hour duration over a period of approximately 30
hours, are required for luteal regression in heifers (Mann and Lamming, 2006). In cattle, P4
decreases during the ascending portion of a naturally occurring uterine PGF pulse but increases
during the descending portion of the PGF pulse. This is due to a pulse of LH stimulated by
decreased P4, as well as loss of the negative effect of PGF. A complete rebound in P4 occurs
after each of a series of pulses of PGF2α before the first luteolytic pulse of PGF2α (Ginther and
Beg, 2013) that causes a terminal decrease in P4.
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Luteal endothelial cells
Luteal endothelial cells contribute to luteal demise. Endothelial cells express PGF2α
receptor (Mamluk et al., 1998), and administration of PGF2α caused degeneration of these cells
(O’Shea et al., 1979) leading to reduced capillary density (Braden et al., 1988) and ultimately to
decreased blood flow to the luteal parenchyma. Endothelial cells appear to be one of the first
cell types to be affected by PGF2α treatment by showing signs of apoptosis (Sawyer et al., 1990).
Endothelial cells and more specifically the luteal endothelial cell product endothelial-I (ET-1),
could mediate the luteolytic actions of PGF2α (Girsh et al., 1995). Choudhary et al., 2005
demonstrated that ET-1 increased concentration of intracellular Ca+2 in bovine luteal
steroidogenic cells in vitro. Additionally, SLC and LLC from mature (day-10) CL responded
with a greater increase in Ca+2 than SLC and LLC of developing (day-4) CL (Choudhary et al.,
2002). However, when different doses of ET-1 or PGF2α were administered to bovine luteal
endothelial cells in vitro, no differences between the developing (day-4) and mature (day-10) CL
were observed (Choudhary et al., 2005). Basal and LH-stimulated P4 were reduced by ET-1 in
the developing and mature bovine CL with similar responses (Choudhary et al., 2005). The
authors concluded that ET-1 is a tonic inhibitor of P4 secretion rather than a mediator of the
action of PGF2α, and does not contribute to the insensitivity of the developing CL to luteolytic
actions.
Luteal immune response
Immune cells such as macrophages, neutrophils, T cells, and eosinophils are present in
both the developing and regressing CL. In the bovine CL, markers of CD5+ or CD8+ T cells
increased during stage IV (days 19-21) of the estrous cycle and from day 16 onward in natural
luteal regression (Penny et al, 1999). Similarly, markers of leukocytes, specifically macrophages
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and T lymphocytes, significantly increased during luteal regression in cattle (Penny et al., 1999;
Bauer et al., 2001). During induced luteolysis of mature bovine CL, mRNA of TNF-α,
interferon gamma (IFN-γ), and interleukin 1-beta (IL-1β) were all increased as soon as two hours
after injection of PGF2α and continued to be elevated throughout 12 hours post PGF2α (Neuvians
et al., 2004). The wide range in time spanned by this influx of cytokines may indicate that they
play roles in both functional and structural regression. Up to 70% of proliferating cells in the
regressing bovine CL are CD14+ macrophages (Bauer et al., 2001). Recruitment of
macrophages to the CL by the cytokine monocyte chemoattractant protein 1 (MCP-1) is
enhanced by the ability of immune and endothelial cells to interact with one another (Shirasuna
et al., 2012). Penny (2000) proposed that on day 18 of the estrous cycle, PGF2α acts on various
cell types in the CL, such as T-lymphocytes, endothelial cells, fibroblasts, and possibly immune
cells directly, to induce MCP-1 production. In the next 24 hours an influx of macrophages
occurs in response to MCP-1, which is proposed to serve as an additional source of MCP-1 as
well as playing an active role in structural regression (Penny, 2000). Additionally, activated
immune cells seem to produce a factor that impairs luteal cell P4 production because PGF2α
enhances the production of luteal chemoattractant, and macrophages and eosinophils decrease P4
secretion in the midphase CL in cattle (Pate, 1995).
Signal Transduction Mechanism
The mechanism governing the action of PGF2α is thought to involve activation of the
phospholipase C-Ca2+ pathway (Davis et al., 1987). The binding of PGF2α to its cognate Gqprotein-coupled receptor causes dissociation of the α subunit from the β/γ subunit. The α subunit
exchanges GDP for GTP to activate phospholipase C (PLC; Davis et al., 1988). Then, PLC
cleaves plasma membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2) to generate free
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IP3 (Berridge et al., 1983) and membrane-bound 1,2-diacylglycerol (DAG) (Berridge, 1987).
Increase in both the concentration of cytoplasmic Ca2+ and activation of PKC are, in part,
intracellular mediators of the actions of PGF2α in luteal cells (Wiltbank et al., 1990). Even
though it is generally referred to as PKC in signal transduction pathways, PKC is a family of
protein kinases that can be divided into three subfamilies: classic (cPKC; α, βI, βII, and γ), novel
(nPKC; δ, ε, η, and θ), and atypical (aPKC; ζ, ι, and λ) (Kang, 2014). Sen et al. (2003)
hypothesized that differential expression of PKC isozymes during the estrous cycle might
explain inability of the developing CL to mount the same luteolytic response to PGF2α that is
seen in the mature CL. Indeed, both PKCε and PKCβII were expressed at higher concentrations
in the mature CL (day 10) compared to the developing CL (day 4). In both developing and
mature CL, PGF2α had the capacity to activate conventional PKC isozymes. Therefore the
authors reasoned that these isozymes do not contribute to the insensitivity of developing CL to
luteolytic actions of PGF2α (Sen et al., 2003). Specific inhibitors of PKCε significantly
decreased the PGF2α-induced rise in intracellular Ca+2 in LLC and SLC that in turn had
consequences (at least in part) in the ability of PGF2α to inhibit LH-stimulated P4 secretion at
this developmental stage (Sen et al., 2005). Additionally, downregulating expression of PKCε
reduced the ability of PGF2α to inhibit P4 synthesis/secretion (Goravanahally et al., 2007).
In other studies, the next intracellular mediator, cytosolic Cat+2, was investigated.
Developmental differences in the ability of PGF2α to induce increases in intracellular Ca+2 have
been demonstrated in both LLC and SLC (Choudhary et al., 2005). In vitro, PGF2α evoked a
larger increase in intracellular Ca+2 in both SLC and LLC from mature (day-10) than developing
(day-4) CL, and percentage of day-10 SLC responding increased as a function of PGF2α
concentration (Choudhary et al., 2005).
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Goravanahally et al., (2009) provided evidence that the luteolytic actions of increases in
intracellular Ca2+ may be mediated through calmodulin dependent kinase kinase 2 beta
(CAMKK2) because mRNA expression of CAMKK2 was upregulated in mature versus
developing bovine CL. Additionally, CAMKK2 gene expression was upregulated in mature
bovine CL when PGF2α was administered in vivo 24 hours before CL removal (Goravanahally et
al., 2009). Whether CAMKK2 affects steroidogenesis directly or indirectly by acting upon
another intermediary target is not known. One such target is adenosine monophosphate activated
protein kinase (AMPK; Wong, 2009) and it is a possible mediator for the luteolytic actions of
PGF2α.

PGF2α signal transduction pathway
Adenosine monophosphate activated protein kinase (AMPK)
Adenosine monophosphate activated protein kinase is an important regulatory protein for
cellular energy balance in multiple cell types. In all eukaryotic cells, AMPK is a heterotrimeric
complex composed of one catalytic subunit α (with two isoforms: PRKAA1 and PRKAA2), and
two regulatory subunits β (with two isoforms: PRKAB1 and PRKAB2) and γ (with three
isoforms: PRKAG1, PRKAG2, and PRKG3) (Wong et al., 2009). Different types of cells and
tissues express distinctly different combinations of these subunits. Activation of AMPK by
phosphorylation of threonine 172 of the α subunit by upstream kinases, LKB1 or CAMKK2, is
required for its activity (Wong et al., 2009). A serine/threonine kinase, LKB1, is the primary
upstream kinase of AMPK and appears to be constitutively active (Hardie, 2008). When energy
concentrations are depleted resulting in a decrease in ATP along with an increase in AMP, LKB1
phosphorylates Thr 172.
Specific tissues, such as neurons and endothelial-derived cells, express an alternate
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pathway for activation of AMPK (Hardie, 2008). Increases in cytoplasmic Ca+2 lead to
activation of CAMKK2, which is capable of phosphorylating AMPK at Thr 172. Free catalytic α
subunits are usually inactive due to the presence of an autoinhibitory domain that is located in
the center of the subunit. Autoinhibition is eliminated when the α subunit forms a functional
complex with the β and γ subunits. The β subunit has key autoregulatory function in the AMPK
complex, partially due to a specific sequence that binds to glycogen molecules (Guzman et al.,
2009). A myristoylation site serves as a switch for reversible membrane binding of the complex,
and a direct autoihibitory domain is located within the β subunit (Guzman et al., 2009). The γ
subunit is defined by the two Bateman domains, which selectively bind molecules that contain
adenosine such as AMP or ATP (Bateman, 1997). The binding of AMP to the γ subunit
activates AMPK by inducing conformational changes in the complex that promote
phosphorylation of Thr172. Binding of ATP inhibits these changes. Phosphorylation by AMPK
of proteins that inhibit anabolic processes, such as those involved in metabolic pathways that
reduce protein synthesis and cell proliferation and increase catabolic pathways that create energy
such as glucose uptake, mitochondrial biogenesis, glycolysis and lipid oxidation (Hardie, 2008).
Recently, activated AMPK has been shown to decrease P4 secretion in rat, cow, and primary F1
hen granulosal cells (Tosca et al., 2005; Tosca et al., 2007; Tosca et al., 2006). All subunits and
their isoforms of AMPK have been characterized in bovine whole ovary, CL, small and large
follicles as well as granulosal cells (Tosca et al., 2007).
Pharmaceutical agents
Thiazolinediones (TZDs) have been used as a form of medication for type II diabetes
mellitus since the 1990’s. This is the only approved use, TZD is being experimentally tested to
treat polycystic ovarian syndrome (PCOS; Belfort et al., 2006), autism (Boris et al., 2007), and
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ovarian hyperstimulation syndrome (Shah et al., 2010). Peroxisome proliferator-activated
receptors (PPAR), which are endogenously activated by free fatty acids and prostanoids, are also
activated by TZDs. Once activated, PPAR dimerizes with retinoid X receptor (RXR) to induce a
specific cohort of gene expression. In general, TZDs decrease triglycerides and increase highdensity lipoprotein cholesterol (HDL-C).
Dorsomorphin dihydrochloride (DM), also known as Compound C, is a potent selective,
cell-permeable and reversible AMPK inhibitor (Liu et al., 2014). Dorsomorphin inhibited
AMPK induced either by 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR)
(Tang et al., 2011) and metformin (Isakovic et al., 2007). However, DM inhibited other kinases
in addition to AMPK (Bain et al. 2007).
One cell-permeable allosteric activator of AMPK is AICAR. It is metabolized
intracellularly to ZMP (5-aminoimidazole-4-carboxamide-1- β-D-ribofuranotide) by adenosine
kinase (Merrill et al., 1997). Phosphorylated AICAR, ZMP, is an AMP analog that interacts with
the γ subunit of AMPK and induces kinase activation through allosteric changes in AMPK
conformation (Merrill et al., 1997). Although AICAR is used extensively in the laboratory, it is
not ideal for clinical scenarios because of its short half-life, requirement for intravenous infusion,
and variable effectiveness among patients (Wong et al., 2009).
Metformin is another well-known activator of AMPK, although it activates the
heterotrimeric complex indirectly. Metformin is a biguanide that is developed from galegine,
which is a derivative of the guanidine found in Galega officinalis (French lilac). Metformin
specifically works in the mitochondria by inhibiting the mitochondrial respiratory chain complex
I. Although the exact mechanism of action has yet to be elucidated, metformin inhibits complex
I without affecting any other steps in the respiratory chain (Viollet et al., 2012). Ultimately,
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metformin reduces the synthesis of ATP by decreasing not only NADH oxidation but also proton
pumping across the inner mitochondrial membrane and rate of oxygen consumption (Viollet et
al., 2012). This reduction in ATP results in a shift in the AMP: ATP ratio and causes the AMPK
complex to become phosphorylated and therefore active (Viollet et al., 2012).
Metformin is the most widely used drug for the treatment of type II diabetes, being
prescribed to nearly 120 million people worldwide (Viollet et al., 2012). It inhibits hepatic
gluconeogenesis and augments the rate of glucose uptake in skeletal muscle (Bailey, 1996).
Recently, metformin was used to treat women experiencing PCOS who were overweight or
insulin resistant. Metformin’s ability to increase insulin sensitivity in individuals made it an
ideal candidate for the treatment of PCOS. Metformin increased insulin sensitivity in patients
with PCOS and it increased ovulation rate, improved menstrual cyclicity, and reduced serum
androgen (Tang et al., 2010). However, in 2007 Legro et al. showed that clomiphene citrate was
superior to metformin in achieving live birth rates in infertile women with PCOS. Metformin
appears to work in PCOS patients by both direct ovarian effects and secondarily through
decreasing insulin resistance. In bovine granulosal cells isolated from small antral follicles
steroidogenesis was affected by metformin treatment (Tosca et al., 2007). Metformin (10 mM)
reduced both P4 and E2 production as well as key enzymes (HSD3β, CYP11A1, and STAR),
with or without FSH and/or IGF1 in the media (Tosca et al. 2007).
Interestingly, metformin is a hydrophilic base that is excreted unchanged in the urine.
Metformin cannot easily diffuse through cell membranes and is not metabolized into other
variants when being eliminated from the body (Gruzman et al., 2009). Metformin is a small
molecule that has many transporters, known as organic cation transporters, in the kidney that
lead to its high rate of renal clearance (Wong et al., 2009).
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Model of activation of AMPK in the corpus luteum
Changes in P4 biosynthesis due to activation of AMPK in the bovine CL stem from
increases in intracellular Ca+2. In addition to activating PKC, rises in Ca+2 activate calmodulin
and therefore CAMKK. The latter is responsible for phosphorylating AMPK and converting it to
its active form that traditionally monitors the energy balance of the cell, but AMPK may not
have this role in steroidogenic cells. Typically, activation of AMPK results in a shift from
anabolic processes, such as synthesis of proteins like enzymes involved in P4 production, to
catabolic processes. Additionally, AMPK activation leads to phosphorylation of fatty acid
synthase (FAS), and acetyl-CoA-carboxylase (ACC1), key enzymes in de novo lipid synthesis.
It may also regulate cholesterol uptake through lipoprotein receptors. Progesterone is a steroid
hormone and is derived from cholesterol that is made up of lipids. This provides another
mechanism to reduce overall P4 production (Figure 1.0).

Statement of the problem
The literature established that developmental differences exist in multiple facets of
physiology between developing and mature bovine CL. Changes in FP expression or PGF2α
ligand, luteal blood flow, endothelial system, immune system, and the signal transduction
mechanism have all been investigated in an attempt to explain the insensitivity of the developing
CL to a luteolytic dose of PGF2α. However, FP receptor expression is similar among developing
and mature bovine CL, and, furthermore, PGF2α- mediated actions have been demonstrated at
these two luteal developmental stages Therefore, a difference in the components of the signal
transduction mechanim activated by PGF2α upon binding to its cognate FP exits between
developing and mature CL. In agreement with this idea, PGF2α elicited a difference in Ca+2
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response between the two developmental stages of the bovine CL, and a down-stream target of
Ca+2, CAMMK2, was differentially expressed in developing and mature CL. CAMKK2 is
known to phosphorylate AMPK, but this component of the signal transduction pathway has not
been investiaged in relation to reproductive endocrinology. Therefore, the goal of this project is
to investigate alternative downstream components activated by the rise in cytosolic [Ca2+]
initiated when the FP receptor is activated in both bovine luteal tissue and luteinized human
granulosal cells. The objectives of the research were: to determine the changes in P4 secretion in
vitro and in vivo in the presence of an AMPK inhibitor or activator in developing and mature
bovine CL; define changes in AMPK that occur as a result of FP activation; define changes in
cholesterol transport that occur as a result of PGF2α binding to FP, which may be monitored by
AMPK; define culture conditions and responses to luteotropic and luteolytic signals by luteinized
human granulosal cells derived from patients with various infertility causes. The proposed
research has one central hypothesis: developmental differences in components of the signal
transduction associated with FP expressed in developing and mature CL explain, at least in part,
the developmental difference in the ability of PGF2α to induce functional luteal regression.
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Figure 1.0: Model of actions of AMPK in luteal cells. Changes in progesterone biosynthesis due
to activation of AMPK in the bovine CL stem from increases in intracellular Ca+2, calmodulin,
and CAMKK2. CAMKK2 phosphorylates AMPK and converting it to its active form results in a
shift from anabolic processes to catabolic processes. Additionally, AMPK may regulate
cholesterol uptake through lipoprotein receptors (LDLR and SRB-1). This provides another
mechanism to reduce overall progesterone production in addition to the established role of PKC.
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Chapter 2: Effects of prostaglandin F 2 alpha and adenosine
monophosphate activated kinase on progesterone production in the
bovine corpus luteum in vivo
Introduction
The ability of bovine corpus luteum (CL) to respond to luteolytic actions of prostaglandin
F 2 alpha (PGF2α) increases after ovulation in cattle. Developing CL (days 1-5) fail to regress if
a single exogenous bolus of PGF2α is given, yet administration of PGF2α at the same dose when
the CL is at the mature stage (days 6-15) will induce regression with the cow returning to estrus
within 48-72 hours (Rowson et al., 1972; Inskeep, 1973). The cellular mechanisms responsible
for this developmental difference are unclear. Lack of receptors (Wiltbank, 1995; Juengel et al.,
1998; Wright et al., 2014) or ability to elicit a physiological response to PGF2α (Tsai and
Wiltbank, 1998; Choudhary et al., 2005; Sen et al., 2005) does not appear to explain the
observed differences. As discussed below, differences in the signal transduction mechanisms
associated with FP receptor might explain some of the characteristics of the elicited response to
PGF2α in mature versus developing CL.
In luteal cells, PGF2α has affects by binding to its cognate Gq protein-coupled receptor
and activating phospholipase C (PLC; Davis et al., 1988). Then, PLC cleaves plasma
membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2) to generate free IP3 (Berridge et
al., 1983) and membrane-bound 1,2-diacylglycerol (DAG) (Berridge, 1987). Water-soluble IP3
increases the concentration of cytoplasmic Ca2+, and DAG, which in combination with Ca2+,
activates protein kinase C (PKC). Increases in both cytoplasmic Ca2+ and activation of PKC
have been demonstrated, in part, to mediate the actions of PGF2α in luteal cells (Wiltbank et al.,
1990). Differential expression of genes encoding particular isoforms of PKCs and genes
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participating in Ca2+ homeostasis have been implicated in acquisition of luteolytic capacity by
the bovine CL. In agreement with this suggestion, increased expression of two PKC inhibitors,
histidine triad nucleotide binding protein (H1NT1) and tyrosine 2-monooxygenase\tryptophan 5monooxygenase activation protein zeta polypeptide (YWHAZ), appear to be involved in
insensitivity of the early ovine CL (Juengel et al., 1998). Indeed, YWHAZ gene expression was
downregulated in mature bovine CL (Goravanahally et al., 2009). Greater concentrations of
PGF2α are needed to elicit Ca2+ responses in steroidogenic cells isolated from developing than
from mature CL (Choudary et al., 2005). Additionally, increased gene expression of CAMKK2,
a down-stream target of Ca2+, is more relevant in the activated signal transduction pathway in
mature than in developing CL (Goravanahally et al., 2009). After an agonist-mediated rise in
intracellular Ca2+ CAMKK2 was activated via phosphorylation by calcium/calmodulindependent kinases (CAMKs) Whether CAMKK2 affects steroidogenesis directly or if it acts
upon another intermediary step that impinges on steroidogenesis is not known.
One intermediary step could be activated adenosine monophosphate activated kinase
(AMPK), which is activated via phosphorylation by CAMKK2 (Wong, 2009). Typically,
activation of AMPK results in a shift from anabolic processes, such as protein synthesis or
progesterone production, to catabolic processes. Activation of AMPK may regulate progesterone
production by altering cholesterol uptake through high and low-density lipoprotein receptors
such as scavenger receptor class B member 1 (SRB-1) and low-density lipoprotein receptor
(LDLR). Cholesterol influx is critical in steroidogenic cells because it is the preferred source
over de novo synthesis in this tissue. Both LDL and HDL provide substrate for progesterone
production. During luteal regression in primates, gene expression for lipoprotein receptors SRB1 and LDLR decreased (Bogan et al., 2009, 2010). Downregulation of LDLR activity in human
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fibroblast cells increased expression of acyl CoA cholesterol acyltransferase (ACAT) (Brown et
al., 1975), which is responsible for esterification of free cholesterol. These cholesterol esters are
stored in lipid droplets and are hormonally regulated in steroidogenic cells of the adrenal, ovary
and testis (Behrman and Greep, 1972; Hou et al., 2010). The possibility that PGF2α predicates
luteolytic actions of AMPK regulation changes in cholesterol transport has yet to be explored in
the bovine CL.
One well known activator of AMPK is metformin, which is the most widely used
pharmaceutical for treatment of type II diabetes being prescribed to nearly 120 million people
worldwide (Viollet et al., 2012). Metformin activates AMPK by reducing synthesis of ATP
through NADH oxidation, which results in a shift in AMP: ATP ratio and phosphorylation of the
AMPK complex (Viollet et al., 2012). In addition, metformin has been used to treat polycystic
ovary syndrome (PCOS) in women who were overweight or insulin resistant. Metformin
directly affects the ovaries and also decreases insulin resistance in PCOS patients. Additionally,
metformin has been shown to reduce progesterone and estradiol production in bovine granulosal
cells isolated from small antral follicles (Tosca et al., 2007). Reduced steroidogenesis resulting
from metformin treatment indicates a potential role in progesterone production in the bovine
ovary.
Therefore, the objective of this study was to investigate if AMPK played a role in the
signal transduction pathway used by FP receptors in mature bovine CL. The specific aims of this
research were to determine changes in progesterone secretion in vivo in response to activation of
AMPK via metformin in mature bovine CL; define changes in protein expression of AMPK,
phosphorylated AMPK (P-AMPK) and steroidogenic acute regulatory (StAR) resulting from FP
activation, and characterize cholesterol transport proteins (LDL, SRB-1, ACAT-1) during
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functional regression after activating FP via exogenous PGF2α. The overall hypothesis is that
luteal developmental differences in signal transduction associated with FP can explain, at least in
part, the differences in the ability of PGF2α to induce functional luteal regression in the mature
but not the developing bovine CL.

Materials and Methods
Non-lactating beef cows were observed twice daily for estrus at approximately 12 h intervals for
30 min per observation. The day when standing estrus was observed was designated as day 0
(d0). The West Virginia University Animal Care and Use Committee reviewed and approved
the protocol for the tissue collection (ACUC # 01-0809).
Experiment 1
Cows (450-700 kg BW) were assigned randomly among treatment groups: day 10 hour 0
(d10-h0; n = 5), day 10 hour 2 (d10-h2; n = 5), day 10 hour 4 (d10-h4; n = 5). Cows received a
subcutaneous injection of PGF2α (25 mg, Lutalyse®; Zoetis Florham Park, NJ) or saline (d10-h0)
0, 2, or 4 hours prior to lutectomy. Corpora lutea (CL) were collected via supravaginal incision
under epidural anesthesia (Casida, 1959) with administration of 6-9 mL of 2% lidocaine (Butler
Company, Columbus, OH). CL were weighed and divided into equal sections for protein
isolation and measurement of luteal progesterone. Tissue for protein isolation was snap frozen in
liquid nitrogen and stored at -80°C; remaining tissue was transported to the laboratory in ice-cold
saline. Tissue for luteal P4was homogenized with an Omni Tissue Homogenizer (Omni
International, Kennesaw, GA) and then frozen at -20°C until assayed for P4via RIA. Blood
samples were collected hourly via caudal venipuncture until CL excision. Samples were allowed
to clot and then centrifuged at 3500 x g for 15 minutes, and serum was collected and stored at 20°C. Serum and CL assayed by RIA for P4 as previously described (Sheffel et al., 1982).
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Luteal proteins were analyzed using semiquantitative Western blotting as previously
described (Sen, 2004). Briefly, protein was isolated from d10-h0, d10-h2 and d10-h4 CL by
homogenizing the luteal tissue in a buffer containing 50 mM Tris HCl, 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 0.1% SDS, 1% Triton-X, protease inhibitors (2 mM
phenylmethylsulfonylfluoride, 5 μg/μl leupeptin, 5 μg/μl aprotinin), and phosphatase inhibitors
(100 mM sodium fluoride, 2 mM sodium orthovanadate, 10 mM sodium pyrophosphate). Sample
protein concentration was determined using a Bio-Rad (Hercules, CA) assay with bovine serum
albumin (BSA; Gibco BRL) as a standard. After concentrations were determined, 100 μg/lane of
protein was loaded for StAR, AMPK, P-AMPK, SRB-1, and LDLR. Proteins were resolved with
a 4-15% gradient polyacrylamide TGX gel (Bio-Rad, Hercules, CA) and transferred to
polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA) using a Bio-Rad Mini
Trans-Blot Cell (Hercules, CA).
Primary antibodies used included 1) StAR antibody (#bs-3670R, Bioss, Boston, MA) at
1:250 (v/v) 2) AMPK antibody (#2532S, Cell Signaling Technology, Danvers, MA) 1:1000 (v/v)
3) P-AMPK antibody (#2537S, Cell Signaling Technology, Danvers, MA) 1:1000 (v/v) 4) LDLR antibody (LS-C146979, LSBio, Seattle, WA) 1:500 (v/v) 5) SRB-1 antibody (#ab24603,
AbCam, Cambridge, MA) (1:1000) 6) and beta actin (A2228; Sigma-Aldrich, St. Louis, MO) at
a dilution of 1:2000 (v/v) and incubated overnight at 4°C with gentle shaking. Secondary
antibodies included goat anti-mouse IRDye 680RD (for actin) diluted to 1:10 000 and goat antirabbit IRDye 800CW (for StAR, AMPK, P-AMPK, LDL-R, SRB-1) diluted to 1:10 000 (v/v)
(#926-68170, #827-08365, Li-Cor, Lincoln, NE). A two-color detection scheme was used to
permit simultaneous probing for target proteins. Band intensity imaging was captured using
Odyssey infrared imaging software and quantified through densitometry (ImageJ Bethesda,
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Maryland). Signal intensity for a protein of interest was standardized to the corresponding
intensity of actin in the same sample. This normalization procedure for semiquantitative
estimation of protein was validated by Sen et al. (2004).

Materials and Methods
Non-lactating beef cows were observed twice daily for estrus at approximately 12 h intervals for
30 min per observation. The day of standing estrus was designated as day 0 (d0). The West
Virginia University Animal Care and Use Committee reviewed and approved the protocol for the
tissue collection (ACUC # 12-1008).
Experiment 2
Cows were assigned randomly to treatment groups, which received 15 (Met-15, n = 4) or
30 (Met-30, n = 4) mg/kg of BW of metformin (New England Mail Order Pharmacy,
Middlebury, VT) every 3 hours for 12 hours on d10 of the estrous cycle. Metformin was
pulverized and dissolved into sterile saline solution before centrifugation at 119 RCF for 5
minutes to remove non-active binding ingredients. Supernatant was collected for infusion, the
pellet was washed; and the supernatant was collected and added to the total infusion volume. An
artificial insemination catheter was passed through the cervix, and metformin was deposited into
the uterus by a syringe connected to the catheter by a 200 μl pipette tip. Based on observations
from this study, a dose of 30 mg/kg BW of metformin (metformin, n = 7) or saline (control,
n = 7) was injected into the jugular vein of cows (n = 7) every 3h for 12 hours. Blood samples
were collected one day prior to and hourly for 12h after the first metformin infusion and then one
and two days after treatment. Blood samples were allowed to clot, and then centrifuged at 3500 x
g for 15 min. Serum was collected and stored at -20°C until assayed by RIA for P4 (Sheffel et
al., 1982) and for metformin (Amini et al., 2005). Serum concentrations of insulin were
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determined by RIA kit (Insulin Coat-A-Count; Diagnostics Products Corporation; Los Angeles,
CA). Signs of estrus were monitored daily for 2 weeks after treatment.
Statistical Analysis
Normalized protein concentrations ratios were tested for normal distribution via the
Shapiro-Wilk test (Shapiro and Wilk, 1965). A one-tailed Student’s t-test was used for
comparison of data sets that had a normal distribution. For data sets that did not have a normal
distribution, a one-tailed Wilcoxon two-group test (Mann-Whitney test) was used.
Concentrations of serum P4 was examined using ANOVA with repeated measures, and serum
concentrations of insulin, as well as luteal P4 content, was examined using ANOVA with
Dunnett’s Method post hoc test. Data were analyzed using JMP and SAS software (JMP®,
Version Pro 11, SAS Institute Inc., Cary, NC, Copyright ©2013; SAS®, Version 9.3, SAS
Institute Inc., Cary, NC, Copyright ©2002-2010). Significance criterion alpha for all tests was
0.05. Data are depicted as the mean ± SEM.

Results
Experiment 1
A decrease in serum P4concentration and luteal P4content at 2 h (2.08 ng/ml vs. 2.96
ng/ml; P = 0.054) and 4 h (1.57 ng/ml vs. 2.96 ng/ml; P = 0.013) was observed after PGF2α
administration (d10-h0 = 5.05 ng/ml; d10-h2 = 2.03 ng/ml; d10-h4 = 1.74 ng/ml) (Figure 1.1).
Changes in protein expression of LDL, SRB-1, AMPK, StAR, and ACAT-1 are shown in Figure
1.2. There was no detection of P-AMPK. A decrease in LDL protein expression was observed
at 2 h (0.79 vs. 0.41; P = 0.09) and at 4 h after PGF2α injection (0.79 vs. 0.13; P = 0.004) (Figure
1.2-A). An increase in ACAT-1 occurred by 4 h (0.67 vs. 0.21, P = 0.010) after PGF injection
(Figure 1.2-B). There was a significant quadratic effect of treatment and time (P = 0.037) for
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AMPK protein expression (Figure 1.2-C). An increase in StAR protein expression was observed
4 h (3.62 vs. 1.25, P = 0.01) after PGF2α injection, but not at 2h (1.02 vs. 1.74, Figure 1.2-D).
There was also a quadratic effect of treatment and time (P = 0.05) for StAR protein expression,
with H4 having the highest ratio (Figure 1.2-D). No difference in SRB-1 protein expression
occurred at either 2 (1.92 vs. 1.74) or 4 h (2.75 vs. 1.74) after PGF injection (Figure 1.2-E).
Experiment 2
The preliminary experiment revealed that even though concentrations of metformin were
detectable in blood after intrauterine administration, which is shown by the representative HPLC
metformin determination from a 30-mg/kg bw cow in Figure 1.3; intravenous administration was
simpler. There was a decrease in serum concentrations of P4 (P = 0.001) with 30 mg (1.01 ±
0.08 ng/ml) of metformin compared to 15 mg (1.33 ± 0.08 ng/ml, Figure 1.3). However, days to
estrus was not different between the groups (x = 21 d ± 1). Figure 1.4 illustrates that in the there
was no difference in P4 between metformin (0.784 ± 0.15 ng/ml) and saline (0.788 ± 0.29
ng/ml). Additionally, there was no difference in insulin concentrations between saline (4.49 ±
0.154 µg/L) and metformin (4.48 ± 0.154 µg/L) treatments (P > 0.05; Figure 1.5), or time to
return to estrus (x = 11 d ± 1).

Discussion
These results corroborate that activation of the FP receptor by exogenous PGF2α causes a
decrease in serum and luteal P4 concentrations (Juengel et al., 1993; Wiltbank et al., 1995; Tsai
and Wiltbank 1998; Atli et al., 2012). Similarly, both serum concentrations and luteal P4 content
decreased by 4 hours after PGF2α administration. These decreases of both serum and luteal P4
were observed as early as 2 h after PGF2α, yet no changes in serum P4 were observed at 1 h after
PGF2α (data not shown). These data established a time frame for the process of functional
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regression after exogenous injection of PGF2α.
During this functional regression, cholesterol transport through LDLR was lower at 2 and
4 h after PGF2α, indicating that substrate transport by these receptors was critical during
reduction of P4 production. Lower LDLR would lead to decreased cholesterol, the substrate for
P4 production. Decreases in LDL receptors reduce 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMG-CoA reductase), catalyzing a rate-limiting step in cholesterol production
(Siperstein, 1970), and increasing ACAT-1 (Brown et al., 1975). Cells adjust to the number of
LDL receptors in order to produce sufficient cholesterol for the metabolic need of the cell
without over accumulation (Brown and Goldstein, 1975). This function is key because cells are
able to keep the concentration of unesterified cholesterol in membranes constant, while
requirements and exogenous supply are fluctuating constantly (Goldstein and Brown, 2009).
The observed increases of ACAT-1 indicate an attempt by the luteal tissue to compensate for
decreases in cholesterol.
No change in SRB-1 in mature CL was observed after PGF2α administration. During
spontaneous luteolysis in primate CL, changes in gene expression or protein concentrations of
SRB-1 were not different between mid-late to functional late CL but were decreased from
functional to functionally regressed late stage CL (Bogan et al., 2009, 2010). Functional late CL
were defined as having been collected on day 14-16 of the menstrual cycle, and functionally
regressed late CL were a subset of those CL from animals with serum P4values less than 0.5
ng/ml (Bogan et al., 2009). Based on the criteria used by Bogan et al. (2009, 2010), the time
points used in the current study after PGF2α was given, could have reflected functional
regression; whereas, the results reported by Bogan et al. reflected structural regression.
Expression of AMPK mRNA has been measured in whole bovine ovaries, small and
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large follicles, oocytes, and CL. Additionally, AMPK-α subunit protein expression was detected
in small and large follicles and their granulosal cells (Tosca et al., 2007). Previous data indicated
a developmental difference in AMPK gene expression between developing and mature CL, with
increased expression in mature bovine CL (Goravanhally, unpublished results). Therefore
activation of AMPK would have a greater effect in the mature than developing CL. Activation
of AMPK using metformin decreased P4 production in bovine granulosal (Tosca et al., 2007)
and luteal cells (Hou et al., 2009). Thus, elevated concentrations of AMPK protein observed 2 h
after FP activation may serve as a mechanism by which both serum and luteal P4concentrations
are decreased. At 4 h after FP activation, P4 concentrations decreased such that AMPK
activation was not required to mediate further decreases in steroid production. No detection of
P-AMPK occurred at either 2 or 4 hours. This may be a result of rapid AMPK phosphorylation.
Park et al. (2002) reported AMPK phosphorylation within 5 seconds in skeletal muscle of rats.
Therefore, time points chosen after PGF2α may have been too late to observe any change in
P-AMPK.
Metformin was delivered successfully into the uterine lumen of the cows, and detection
of its presence in serum was achieved using HPLC. This delivery method was chosen originally
due to the concept that counter-current exchange in the utero-ovarian vein (McCracken et al.,
1999) would aid in delivery of metformin to the CL. Despite the fact that metformin was
detectable in blood, passing the AI rod through a cow in the luteal phase was technically
difficult. Differences in P4 concentration were observed between 15 and 30 (mg/kg of BW)
doses of metformin during the preliminary study. The 30 mg dose was chosen based on studies
in horses, in which metformin was being used as treatment for insulin resistance (Hustace et al.,
2009; Rendle et al., 2013). This observation combined with the lack of visible negative side

37

effects of metformin on cows, indicated that a 30 mg/kg of BW dose would be appropriate for IV
administration in subsequent experiments. However, at this dose there was no difference in P4
concentrations between the metformin- and saline-treated cows, and no difference in their time to
return to estrus. Additionally, no changes in insulin concentrations after metformin were
observed. This was surprising because this same dose caused a significant decrease in insulin
concentrations in horses (Rendle et al., 2013). A greater dose of metformin might have elicited a
response in both insulin and P4 production. This would be difficult to test due to the cost
prohibitive nature of administering a drug that is used in the human market to treat patients with
PCOS (Tang et al., 2010) and diabetes (Viollet et al, 2012).
In summary, activation of the FP receptor caused a decrease in luteal and serum
P4concentrations as soon as two hours after exogenous administration PGF2α. Alterations in
cholesterol transport accounted for this reduction, at least in part, in P4production. Changes in
AMPK protein during this same time period indicate that it may be the downstream target of FP
activation, which controls cholesterol trafficking.
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A

Serum progesterone (ng/ml) = 2.9742 - 0.3399*Time from PGF2α (Hour)

	
  

B

Luteal progesterone (ng/ml) = 4.498 - 0.7984*Time from PGF2α (Hour)

Figure 1.1: Bivariate fit of serum (A) and luteal (B) P4 (ng/ml) by time from PGF2α (hour).
Significant declines in serum and luteal progesterone occurred at both 2 and 4 hours after PGF2α.
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Figure 1.2: Semiquantitative analysis of the densitometric data derived from Western blots using
protein samples isolated mature bovine CL 0, 2, and 4 hours after PGF2α. The y-axis shows the
ratio of the optical density (o.d.) for the protein of interest corrected by the detected o.d. for its
corresponding actin. The data are given as mean ± SEM; values with differing letters denote
statistically significant differences (P < 0.001).
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Serum Progesterone after IU Metformin
Progesterone (ng/ml)
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Figure 1.3: A-Serum progesterone values for 15 or 30 (mg/kg of bw) IU of metformin. Serum
progesterone was significantly lower 12 hours after starting treatment (P < 0.001) when cows
received 30 mg/kg bw than when cows received 15 mg/kg bw. B-Representative HPLC graph of
metformin concentrations in a cow receiving 30/mg kg of bw.
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Figure 1.4: Serum progesterone concentrations pooled across all experiments showed that there
was no difference in metformin-treated (n = 7) versus saline-control (n = 7)cows.
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Figure 1.5: Serum insulin concentrations one day prior to and during metformin treatment. Cows
were given 30 mg/kg bw of metformin IV or sterile saline for control cows every 3 hours over 12
hours, during the day of treatment. No significant difference of treatment or time was seen in
insulin concentrations.
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Chapter 3: Adenosine monophosphate activated protein kinase activation in
vitro modulated progesterone secretion in mature but not developing bovine
CL
Introduction
The mechanisms governing the action of prostaglandin F 2 alpha (PGF2α), are
incompletely known. Nevertheless, this mechanism involves activation of the phospholipase CCa2+ pathway (Davis et al., 1987). In luteal cells, PGF2α has affects by binding to its cognate Gq
protein-coupled receptor and activating phospholipase C (PLC; Davis et al., 1988). The PLC
cleaves plasma membrane-bound phosphatidylinositol 4,5-bisphosphate (PIP2) to generate free
IP3 (Berridge et al., 1983) and membrane-bound 1,2-diacylglycerol (DAG; Berridge, 1987),
which increases Ca2+ and activates protein kinase C (PKC), respectively. Increases in both
concentrations of cytoplasmic Ca2+ and activation of PKC have been demonstrated to mediate
intracellular actions of PGF2α in luteal cells (Wiltbank et al., 1990). Differential expression of
genes associated with Ca2+ homeostasis plays a role in the development of luteolytic capacity of
bovine CL. Greater concentrations of PGF2α are needed to elicit Ca2+ responses in steroidogenic
cells isolated from developing than from mature CL (Choudary et al., 2005). Additionally, gene
expression of CAMKK2, a down-stream target of Ca2+, is increased in mature CL
(Goravanahally et al., 2009). The serine/threonine protein kinase CAMKK2 has been reported to
mediate the action of intracellular Ca2+ via phosphorylation of calcium/calmodulin-dependent
kinases (CAMKs). Whether CAMKK2 affects steroidogenesis or rather acts upon another
intermediary to mediate its effects is not known. One target of CAMKK2 is adenosine
monophosphate activated protein kinase AMPK (Wong, 2009). The kinase CAMKK2
phosphorylates AMPK, but this particular component of this signal transduction pathway has not
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been investigated in the bovine CL.
In multiple cell types, AMPK is an important regulatory protein for energy balance. In
all eukaryotic cells it is a heterotrimeric complex composed of one catalytic subunit α (with two
isoforms: PRKAA1 and PRKAA2) and two regulatory subunits β (with two isoforms: PRKAB1
and PRKAB2) and γ (with three isoforms: PRKAG1, PRKAG2, and PRKG3; Wong et al.,
2009). Increases in cytoplasmic Ca+2 lead to activation of CAMKK2, which is capable of
phosphorylating AMPK at Thr 172. Binding of AMP to the γ subunit activates AMPK by
inducing conformational changes in the complex that promote phosphorylation of Thr172.
Typically, activation of AMPK results in a shift from anabolic processes (Hardie, 2008), such as
synthesis of proteins that are required for progesterone (P4) production, to catabolic processes.
Recently, activated AMPK decreased P4 secretion in murine, bovine, and primary F1 galline
granulosal cells (Tosca et al., 2005; Tosca et al., 2006; Tosca et al., 2007). All subunits of
AMPK and their isoforms were present in whole ovaries, CL, small and large follicles as well as
granulosal cells in the cow (Tosca et al., 2007). AMPK is activated in response to the
antidiabetic drug metformin (Viollet et al., 2012), and by 5-Aminoimidazole-4-carboxamide-1-β4-ribofuranoside (AICAR), a cell-permeable allosteric AMPK activator (Corton et al., 1995).
Dorsomorphin dihydrochloride (DM) is a potent, selective, cell-permeable and reversible AMPK
inhibitor (Liu et al., 2014). It inhibited AMPK induced either by AICAR (Tang et al., 2011) or
metformin (Isakovic et al., 2007). If CAMKK2 targets AMPK in bovine CL, increased gene
expression of CAMKK2 during this developmental stage may lead to increased AMPK
activation, and, therefore, become an additional mechanism to mediate effects of PGF2α.
The goal of this project was to investigate alternative downstream components activated
by the rise in cytosolic [Ca2+] initiated when the FP receptor is activated in bovine luteal tissue.
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The objectives of this research were to determine the changes in P4 secretion in the presence of
AMPK activators or inhibitor in developing and mature bovine CL in vitro. Developmental
differences in components of signal transduction associated with AMPK activation in developing
and mature CL may explain, at least in part, the developmental differences in the ability of
PGF2α to induce functional luteal regression.

Materials and Methods
Animal Handling and Surgical Procedures
Non-lactating beef cows were observed twice daily for estrus at approximately 12 h intervals for
30 min per observation. The day when standing estrus was observed was designated as day 0
(d0). The West Virginia University Animal Care and Use Committee reviewed and approved the
protocol for the tissue collection (ACUC # 01-0809).Ovaries (d4; n = 5) or CL (d10; n = 5) were
collected via supravaginal incision under epidural anesthesia (Casida, 1959) and transported in
ice-cold saline to the laboratory. Connective tissue was removed prior to obtaining weights and
slicing for treatment.
Luteal Slice Incubation Procedure
Luteal slices were incubated for 30 min with 500 µl of minimum essential media (MEM, Life
Technologies, Grand Island, NY) and pharmaceutical agents before hormones were added.
Media were removed, and fresh media added back along with treatments for 2 hr incubation at
37°C, shaking at 200 rpm. Progesterone was assayed by radioimmunoassay (RIA) as previously
described (Sheffel et al., 1982).
Experiment 1
Luteal slices were treated with MEM (control), PGF2α (1.0 μg/ml), DM (10.9 µM/L, Tocris,
Bristol, UK), or DM (10.9 µM/L) and PGF2α (1.0 μg/ml). Media were collected and frozen at 46

20°C until assayed for P4.
Experiment 2
Luteal slices were treated with MEM (control), PGF2α (PGF2α, 1.0 μg/ml), metformin (Met; 10,
5, 1, 0.5, 0.1 mM; New England Mail Order Pharmacy, Middlebury, VT), or AICAR (7.5, 0.75,
0.075 mM, Tocris, Bristol, UK). After incubation, slices were homogenized using an Omni
Tissue Homogenizer (Omni International, Kennesaw, GA) in incubation media and frozen at 20°C until assayed for P4.
Statistical Analysis
Progesterone values were analyzed using ANOVA followed by Dunnett’s Method for means
comparisons to control. T-Test was used to compare the value of progesterone at the highest dose
of metformin and AICAR with control values in both D4 and D10. Data were analyzed using
JMP and SAS software (JMP®, Version Pro 11, SAS Institute Inc., Cary, NC, Copyright ©2013;
SAS®, Version 9.3, SAS Institute Inc., Cary, NC, Copyright ©2002-2010). Significance
criterion alpha for all tests was 0.05. Data are depicted as the mean ± SEM.

Results
Experiment 1
No significant effects of PGF2α (0.94 ± 0.13; P = 0.96), DM (1.921 ± 1.3, P = 0.39), or PGF2α
and DM (1.11 ± 0.53; P = 0.91) were observed on P4 production when compared to basal values
(1.00 ± 0) in d4 CL. In d10 CL, PGF2α increased P4 production (2.4 ± 0.35 vs 1.00 ± 0; P =
0.0003), while DM treatment alone (1.34 ± 0.11 vs. 1.00 ± 0) had no effect (P = 0.24).
Stimulatory effect of PGF2α was eliminated when DM was added, such that P4 values did not
differ from controls (1.85 ± 0.54 vs 1.00 ± 0; P = 0.31) but were different from PGF2α alone
(1.34 ± 0.11 vs 2.421 ± 0.35; P = 0.0037).
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Experiment 2
No significant effect of metformin (P = 0.91) or AICAR (P = 0.51) at any concentration was
observed in D4 CL. A decrease in basal P4 was observed with both metformin (0.39 ± 0.20; 10
mM; P = 0.006) and AICAR (0.40 ± 0.15; 7.5 mM; P = 0.0117) in D10 CL when compared to
control (0.99 ± 0.32).

Discussion
These results indicate that AMPK is involved in the signal transduction mechanism of the
mature but not developing bovine CL. No significant changes were observed in P4 production
when d4 luteal tissue was treated with DM, metformin, or AICAR. However, d10 CL responded
to all AMPK activators with a significant inhibition in P4 production, and the AMPK inhibitor
eliminated this effect. All subunits of AMPK are present in the bovine ovary (Tosca et al.,
2007), but gene expression of these subunits might change throughout development of the CL.
In fact, Goravanahally (unpublished results) demonstrated that, with the exception of AMPKγ1
and AMPKγ2, mRNA expression of AMPK subunits were increased in the mature CL
(P < 0.05). Moreover, an additional observation supporting the interpretation that the effects of
increases in cytosolic calcium are conveyed via CAMKK2-AMPK was that a CAMKK2
inhibitor, STO-609, blocked the inhibitory effects of PGF2α in dispersed mature bovine luteal
cells (Goravanahally, unpublished results). STO-609 also inhibited PGF2α-induced
phosphorylated state of AMPK (P-AMPK) in mature but not developing bovine CL.
Collectively, these data demonstrate that the signal transduction pathway involving CAMKK2
and AMPK regulates luteal function in the mature, but not the developing CL.
Tosca et al. (2005, 2006, 2007) have provided evidence in the rat, hen, and cow that
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AMPK is involved in steroid production in granulosal cells. It is not surprising that AMPK plays
a role in steroidogenesis of luteal cells, as this population is derived from granulosal cells. In
agreement with previous results, these data reveal that metformin and AICAR decreased basal P4
production. The effects of DM were developmentally different; DM had no effect on P4
production in developing CL, but blocked the stimulatory effects of PGF2α in mature CL.
However, lower doses of metformin (5, 1, 0.5, 0.1 mM) or AICAR (0.75, 0.075 mM) did not
affect P4 production. Doses of both AMPK activators were based on previous reports, in which
a significant decline in basal P4 production was seen in vitro (Tosca et al., 2005; Tosca et al.,
2007). However, CL tissue from this study was incubated for 2 hours before collection,
compared to the range of 3 to 48 hours in the previous study with bovine granulosal cells (Tosca
et al., 2007). Differences in P4 were significant at 2 hours of incubation, but longer incubation
times with lower doses may have decreased steroid production.
In conclusion, DM eliminated the effect of PGF2α on mature but not developing bovine
CL. Higher doses of metformin and AICAR were capable of decreasing P4 in mature but not in
developing bovine CL. This developmental difference in signal transduction may play a
significant role in the ability of mature CL to regress in response to a single luteolytic dose of
PGF2α.
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Figure 2.1-DM reduced the stimulatory effect of PGF2α on P4 secretion in mature (D10) but
neither PGF2α nor DM alone or in combination with PGF2α or LH were affected in the developing
CL (D4). Luteal slices were incubated for 30 minutes in MEM and DM without hormones after
which all media were removed, and fresh MEM, DM and hormones were added back. Media
were collected and frozen until analyzed for progesterone with RIA. Different letters indicate
significant differences at (P < 0.05).
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Figure 2.2: Neither PGF2α nor its activators, metformin and AICAR, had any significant effect on
basal progesterone production in developing (D4) bovine CL. Luteal slices were incubated for 30
minutes in MEM and metformin or AICAR without hormones after which all media were
removed, and fresh MEM, metformin or AICAR and hormones were added back. Slices were
homogenized in the media and then collected and frozen until analyzed for progesterone with
RIA. Different letters indicate significant differences at (P < 0.05).
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Figure 2.3: At the greatest concentrations tested, both metformin and AICAR significantly (P <
0.05) decreased basal progesterone production in mature (D10) bovine CL. Luteal slices were
incubated for 30 minutes in MEM and metformin or AICAR without hormones after which all
media were removed, and fresh MEM, metformin or AICAR and hormones were added back.
Slices were homogenized in the media and then collected and frozen until analyzed for
progesterone with RIA. Different letters indicate significant differences at (P < 0.05).
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Chapter 4: Primary infertility affects progesterone production by
luteinized human mural granulosal cells in vitro
Introduction
Follicles, comprised of the oocyte, granulosal and thecal cells, are the functional unit of
the ovary. The somatic cells in the outermost vascular portion of the follicle include thecal and
myoepithelial cells. The avascular component of the follicle is delimited by a basement
membrane upon which the other somatic cells of the follicle, the granulosal epithelial layer and
the germ cell reside. Two populations of granulosal cells have been identified: mural and
cumulus granulosal cells. Both populations of cells are organized as a stratified epithelium with
the basal layer of mural cells contacting the basement membrane adjacent to the thecal cells and
the cumulus cells surrounding the oocyte (Buccione et al., 1990). Mural granulosal cells express
receptors for FSH and LH as well as the enzymes 3β-HSD and P450scc (Zoller and Weisz,
1979). Expression of these two enzymes is representative of a luteal characteristic in these cells,
while cumulus granulosal cells remain with the oocyte even after ovulation (Russell and Salustri,
2006). Once ovulation has occurred, mural granulosal cells lose their ability to proliferate,
undergo epithelial-mesenchymal transition and differentiate into large luteal cells (LLC) of the
corpus luteum (CL), which secrete high amounts of basal progesterone (P4; Chaffkin et al.,
1992). Interestingly, P4 receptors (PGR) cannot be detected with immunohistochemical analysis
in human granulosal cells at any follicular stage but they are detected readily in human luteal
tissue (Suzuki et al., 1994). The fact that PGR is absent in preovulatory follicles but present in
periovulatory follicles and in the CL after a surge of gonadotropins supports the hypothesis that
LH induces PGR expression (Hild-Petito et al., 1988). Thecal cells become small luteal cells
(SLC) once luteinization has occurred.
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In the CL of primates, granulosal and thecal cells remain as two distinct populations and
are separated by the remnants of the follicular basement membrane (Guraya, 1971). In contrast,
the basement membrane separating these two cell populations is remodeled, and thecal cells,
which become SLC, invade the granulosal cells to form a heterogeneous mixture of cells in the
CL of nonprimate species (Niswender, 2000). Rescue of the CL during the fertile cycle by
human chorionic gonadotropin (hCG) is essential for maintenance of pregnancy once the oocyte
is fertilized. Infertility is a problem that affects millions of women and their partners across the
United States. Causes of infertility range from ovulatory dysfunction to male related infertility
due to abnormal sperm motility or morphology. Insufficient luteal rescue can account for
pregnancy loss in couples conceiving naturally as well as those that have undergone time
consuming and expensive procedures such as intrauterine insemination or in vitro embryo
production.
Human granulosal cells that have been recovered during oocyte retrieval in patients
undergoing in vitro fertilization spontaneously luteinize in culture, thus these cells have been
used as a model to study granulosal-lutein cells of the CL (Stewart and Vandevoort, 1997). The
degree of luteinization of these cells has not been clearly defined, and studies using them do not
take into account the heterogeneity of a granulosal cell population or the fertility status of the
patient from whom they were isolated. Using patient cause of infertility as an experimental
variable offers a unique opportunity to study how infertility affects P4 production by luteinized
granulosal cells when subjected to hormonal treatments.
In multiple species, PGF2α elicits both inhibitory and stimulatory P4 responses in luteal
cells in vitro. Most investigators use a non-physiological dose of PGF2α when treating luteal
cells in vitro. The fact that PGF2α at high concentrations is able to activate the PGE2 receptor
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could, in part, explain increases in P4 production (Rao, 1974). Additionally, the entire
population of cells that would normally be present in addition to luteinized granulosal cells is not
present in all in vitro experiments. Inhibitory action of PGF2α on human luteinized granulosal
cells may be enhanced by presence of endothelial and/or immune cell types (Liptak et al., 2005).
In multiple cell types, AMPK is an important regulatory protein for energy balance.
Typically, activation of AMPK results in a shift from anabolic processes (Hardie, 2008), such as
synthesis of proteins that are required for progesterone production, to catabolic processes. The
antidiabetic drug metformin activates AMPK (Viollet et al., 2012), and by 5-Aminoimidazole-4carboxamide-1-β-4-ribofuranoside (AICAR), a cell-permeable allosteric AMPK activator
(Corton et al., 1995). Dorsomorphin dihydrochloride (DM) is a potent, selective, cell-permeable
and reversible AMPK inhibitor (Liu et al., 2014), and DM inhibited AMPK induced either by
AICAR (Tang et al., 2011) or metformin (Isakovic et al., 2007). Metformin is the most widely
used drug for the treatment of type II diabetes, being prescribed to nearly 120 million people
worldwide (Viollet et al., 2012). Recently, metformin was used to treat women experiencing
PCOS who were overweight or insulin resistant. Metformin’s ability to increase insulin
sensitivity in individuals made it an ideal candidate for the treatment of PCOS. Metformin
increased insulin sensitivity in patients with PCOS, and it increased ovulation rate, improved
menstrual cyclicity, and reduced serum androgen (Tang et al., 2010). Metformin appears to
work in PCOS patients by both direct ovarian effects and secondarily through decreasing insulin
resistance. In bovine granulosal cells isolated from small antral follicles metformin has been
shown to have effects on steroidogenesis (Tosca et al., 2007). Metformin (10 mM) reduced both
progesterone and estradiol production as well as key enzymes (HSD3β, CYP11A1, and STAR)
with or without FSH and/or IGF1 in the media (Tosca et al. 2007).
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The goal of this project was to investigate the use of human mural granulosal and
cumulus cells to study potential downstream targets activated by the known intracellular
mediators, AMPK and Ca+2, of luteolytic actions of PGF2α actions in bovine luteal cells.
Additionally, it was hypothesized that P4 stimulatory and inhibitory responses to hCG and
PGF2α, respectively, would differ among infertility types. The objectives of this research were to
define culture conditions and responses of luteinized human granulosal cells derived from
patients with various infertility causes to luteotropic and luteolytic signals and to determine
effects of increasing intracellular Ca+2 from low to high values on P4 production. The proposed
research had one central hypothesis: luteinized mural granulosal cells can be used to study how
infertility influences luteal efficiency and the effects of increasing intracellular Ca+2 on P4
production in order to determine if providing the known intracellular mediator of the best known
luteolytic factor, PGF2α, could directly induce a reduction of P4, which is the hallmark event
underlying luteal regression.

Materials and Methods
Patients
Mural and cumulus granulosal cells from patients affected by different causes of
infertility were provided by the WVU Center for Reproductive Medicine in Morgantown, WV
after patient’s ovaries were stimulated for transvaginal oocyte collection for in vitro fertilization
(IVF). Patients ranged in age from 25-40 years of age, had a BMI range of 18.9 to 44.3, and
presented with primary infertility types of male factor (male, n = 5), endometriosis (endo, n = 6),
tubal factor (tub, n = 12), and unexplained/other (other, n = 3). Daily or twice daily injections of
recombinant follicle stimulating hormone (FSH) began on d2 or d3 of the cycle and continued
until ovulation was induced with hCG. Patients returned at least every other day for ultrasonic
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monitoring of follicular growth beginning four days after stimulation. To prevent premature
ovulation, GnRH agonist injections began when follicles reached at least 14 mm in diameter.
Ovulation was induced with hCG injection once follicles were ≥ 18 mm in diameter, followed by
oocyte collection 34 h later.
Isolation and culture of primary human GCs
Follicular aspirates from each patient were centrifuged at 10,000 rpm for 5 min at room
temperature. Supernatant was discarded, and the pellet was resuspended in 500 µl of
DMEM/F12 (Invitrogen, Grand Island, NY) with 20% (v/v) fetal bovine serum,
insulin/transferrin/selenium B (1000; 555; 0.67 mg/L respectively; Gibco, Grand Island, NY),
gentamicin/amphotericin (10 µg/ml-0.25µg/ml; Gibco, Grand Island, NY), and
penicillin/streptomyocin (100 I.U./ml, 100 µg/ml; Life Technologies, Grand Island, NY). Viable
cell number was determined using trypan blue dye exclusion and hemocytometer. Cells were
plated at 10,000 cells per well in 96-well flat bottom culture plates with 300 µl DMEM/F12
media (NUNC, Scientific Laboratory Supplies, Wilford, Nottingham, UK) at 37°C and 5% CO2
in a humidified incubator to permit luteinization and cell attachment. Media was changed every
24 h whereby150 µl of spent media was replaced with fresh DMEM/F12 with serum. Four days
after collection, cells were transferred to serum free DMEM/F12 media, and treatments were
administered. Every treatment was tested in triplicate for each patient and media pooled for P4
by radioimmunoassay (RIA) as previously described (Sheffel et al., 1982).
Experiment 1
Cells were treated with PGF2α (0.1 μg/ml), human hCG (5 IU/ml), or a combination of both
PGF2α and hCG. Cells were cultured further for 24 h after which medium was removed and
frozen at -20°C until assayed for P4. Primary cause of infertility (male factor, endometriosis,
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tubal factor, and unknown), age (< 30, 30-35, 36-40 years of age), BMI (normal = 18.5-24.9,
overweight = 25-29.9, obese > 30), and pregnancy outcome (non-pregnant, and pregnant) were
examined separately due to the variability among patients in these categories.
Experiment 2
Cells were treated with an intracellular calcium buffer 1,2-bis (o-aminophenoxy) ethaneN,N,N',N'-tetraacetic acid, BAPTA (500, 50, 5, 0.5 µmol, Tocris, Bristol, UK) or a calcium
ionophore A23187 (1, 0.1, 0.01, 0.001, 0.0001, 0.00001, 0.000001 µmol, Tocris, Bristol, UK) to
determine effects of altering intracellular Ca+2 on P4 production in luteinized human granulosal
cells. Treatment concentrations of BAPTA and A23187 and incubation times were based on
previous studies with bovine luteal steroidogenic cells and preliminary studies testing 1, 3, and
24 h incubation times in mural granulosal cells, respectively. The medium for the control group
contained 0.1% dimethylsufoxide (DMSO, Pierce Rockport, IL), the solvent used for BAPTA
and A23187. Cells were treated with BAPTA or A23187 for 1 hour, and medium was removed
and frozen at -20°C until assayed for P4.
Experiment 3
Under the same culture conditions, mural granulosal cells were treated with DM (109, 10.9, 1.09,
0.109 µm/L, Tocris, Bristol, UK) or AICAR (7.5, 0.75, 0.075, 0.0075 mM, Tocris, Bristol, UK )
to evaluate the roles of inhibiting/stimulating AMPK, respectively, in luteinized mural granulosal
cell P4 production. Cells were cultured for further 24 h and medium was removed and frozen at
-20°C until assayed for P4.
Experiment 4
Due to stimulation of P4 that was observed when cells were treated with PGF2α it was
hypothesized that this increase was due to promiscuous binding to another PG receptor, such as
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PGE2, which is known to increase P4. To test this hypothesis, mural granulosal cells were
cultured with media alone (control), PGF2α, PGF2α antagonist (AL 8810; 1.0 µmol, Cayman
Chemical, Ann Arbor, MI), and PGF2α and AL 8810. Preliminary dose response studies for
AL 8810 at 10, 1, and 0.1 µmol were conducted in order to find an optimum dose for experiment
4. The medium for the control group contained 0.1% dimethylsufoxide (DMSO; Pierce,
Rockport, IL), the solvent used for AL 8810. Cells were preincubated with AL 8810 for 30 min,
treatments were administered and cells cultured for 24 hours. Medium was collected and frozen
at -20°C until assayed for P4. Additionally, the effect of PGF2α and hCG on P4 production in
cumulus cells was tested.
Statistical Analysis
Concentrations of P4 were tested for normal distribution via the Shapiro-Wilk test. All
data were transformed using natural logarithm. The one-tailed Student t-test was used to
examine P4 production in A23187 experiments. All other experiments were analyzed using
ANOVA and Dunnett’s post hoc test. Data were analyzed using JMP and SAS software (JMP®,
Version Pro 11, SAS Institute Inc., Cary, NC, Copyright ©2013; SAS®, Version 9.3, SAS
Institute Inc., Cary, NC, Copyright ©2002-2010). Differences were considered significant when
P < 0.05. Data in all graphs are depicted as the mean ± SEM.

Results
Experiment 1
There was an increase in P4 production in cells treated with hCG who had been collected
from patients that presented with male infertility factor compared to control (P = 0.0045; Figure
3.1-A), but not in patients who presented with tubal, endometriosis, or diminished ovarian
reserve factor (P > 0.05; Figure 3.1-B,C,D). No significant differences in P4 were seen when
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granulosal cells were treated with PGF2α across all infertility types (P > 0.05). Additionally,
hCG elicited a significant increase in P4 production in patients in the age range of 30-35 (n = 15;
P = 0.008) and 36-40 (n = 6; P = 0.04), but not in patients in the ranges of 25-30 (n = 4; P =
0.73) (Figure 3.2). Patients with normal BMI (18.5-24.9, n = 16) had a significant increase in P4
production when treated with hCG (P < 0.0001), but granulosal cells of patients who were
categorized as overweight (BMI of 25-29.9, n = 6) or obese (BMI >30, n = 3) did not have a
significant increase in P4 production when stimulated with hCG (P > 0.05) (Figure 3.3). Figure
3.4 demonstrates that granulosal cells from patients who became pregnant to the IVF cycle had
significantly greater P4 production when stimulated with hCG (3.23 ng/ml; P = 0.0018 vs.
control) than those who did not become pregnant (1.57 ng/ml; P > 0.05 vs. control).
Experiment 2
A significant reduction in P4 production was found with all concentrations of AICAR except the
lowest (0.0075) when compared to control (P < 0.001). However, no difference was observed
when cells were treated with DM at any concentration (P > 0.05).
Experiment 3
There was a trend (P = 0.062) for PGF2α treatment to increase P4 production in mural granulosal
cells (Figure 3.6-A). The PGF2α receptor antagonist, AL 8810, did not block this stimulation.
However, there was a signficant difference between controls and PGF2α and AL 8810 in
combination (P = 0.024). Cumulus cells responded to hCG stimulation with a signficant
increase in P4 production (P = 0.045), but no difference in P4 was observed when cumulus cells
were treated with PGF2α or PGF2α and the PG antagonist (Figure 3.6-B).
Experiment 4
Progesterone production was increased in mural granulosal cells by A23187 at 0.01 µmol
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(P = 0.041), and a trend (P = 0.096) was observed at 0.1 and 1.0 µmol concentrations tested in
comparison to control concentrations. There was a cubic trend for the effect of BAPTA
concentration on P4 production (P = 0.093) in mural granulosal cells.

Discussion
Data from experiment 1 supported the conclusion that types of infertility affect the ability
of luteinized mural granulosal cells to respond to the luteotropic factor, hCG, in vitro. Knowing
the cause of a patient’s infertility prior to cell culture experiments offers a unique model to study
how infertility affects P4 production by luteinized granulosal cells subjected to hormonal
treatments. Failure of these cells to respond to hCG in vivo could lead to luteal insufficiency or
even early regression of the corpus luteum, resulting in pregnancy loss. Implementing different
post-implantation hormonal treatments based on specific causes of infertility could lead to
increased pregnancy rates while keeping the number of multiple gestations low.
Interestingly, mural cells of women who did not become pregnant had significantly lower
P4 production when stimulated with hCG, when compared to the mural cells of pregnant women.
Failure of these cells to secrete high levels of P4 in vivo is similar to a condition known as luteal
phase defect (LPD). In LPD is a brief elevation in P4 secretion (typically < 11 days) after
ovulation, and is reported to occur in up to 20 percent of women (Balasch and Vanrell, 1987).
This short luteal phase may be due a defect in the process of luteinization or progesterone
production. However, it was postulated by Strott et al. (1970) that luteal phase defect occurs as a
result of low preovulatory FSH levels. This leads to abnormal follicular development and
subsequent inadequate luteinization and/or luteal function. This condition occurs despite normal
LH stimulation at the time of the ovulatory surge (Strott et al., 1970). This could be the case in
the cells from patients who did not become pregnant, where inadequate FSH levels resulted in

61

the mural granulosal cells being unable to respond to hCG. These experiments were performed
four days after oocyte retrieval, which is later than when embryos are normally transferred at the
WVU CRM. It would be interesting to stimulate cells sooner to determine if they could be used
as a predicator of pregnancy success prior to embryo implantation. If these cells could be used
as a diagnostic tool, it could save patients and embryologists substantial time and monetary
resources.
It was not surprising that P4 production by mural granulosal cells was affected by patient
age. The ability to conceive naturally, which decreases as women age; naturally decreases by
11% from 30-34, and another 12% from ages 35-40 (Leridon, 2004). Decreased fertility may be
explained partially by luteal insufficiency. The fact that luteinized mural granulosal cells did not
respond to hCG with increases in P4 leads to the implication that luteal cells derived from these
follicles would not respond sufficiently. Surprisingly, the age group that did not have an
increase in P4 production was the youngest age group. Types of primary infertility were
represented well in this group, but the small population size (n = 4) may explain this anomaly. In
contrast, it was encouraging to see that mural cells from older patients responded to luteotropic
hCG.
Patients with BMIs in the overweight or obese range did not respond to hCG with
increased P4 production. The interrelationship between nutritional status and reproduction is
complicated, and the mechanisms connecting the two are not well defined. However, insulin,
glucose, IGF-1, and leptin all impinge on follicular development directly or influence
gonadotropins at the hypothalamic level. As BMI and adiposity increase so do leptin, and
insulin resistance. It will be critical to ascertain if the mural cells of overweight and obese
patients have insufficient substrate to produce P4 when stimulated or if they are resistant despite
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adequate substrate. Women with PCOS are often obese as well as insulin resistant, and are
prescribed insulin-sensitizing medicines such as metformin (Tang et al., 2010).
Metformin works, in part, by activating AMPK, a key regulator of energy homeostasis
that has direct effects on P4 production in bovine (Tosca et al., 2007), galline (Tosca et al., 2007)
and rodent (Tosca et al., 2005) granulosal cells. Using another AMPK activator, AICAR, a
significant decrease in P4 was seen at all concentrations tested. A decrease in P4 production has
been shown in mature but not developing bovine CL, as mentioned earlier in this dissertation.
This decrease in P4 could be explained by a decrease in key enzymes such as 3βHSD, P450scc,
or StAR, all of which decreased in rat granulosal cells (Tosca et al., 2005). In contrast, no
difference in P4 production was seen when mural cells were treated with an AMPK inhibitor,
DM. The concentrations of DM chosen for experiment 2 were based on studies in bovine CL, in
which DM significantly decreased P4 production. Possibly, a greater concentration of DM was
needed to elicit a change in P4 production in human mural granulosal cells.
A stimulatory effect of PGF2α has been observed consistently over time and has been
attributed by some to the use of non-physiological doses of PGF2α in vitro, which activate other
prostaglandin receptors (Rao et al., 1974). Progesterone stimulation was observed in mural
granulosal cells but not in cumulus granulosal cells (Figure 6). A specific PGF2α receptor
antagonist was unable to eliminate this effect in mural cells, indicating that the stimulation of P4
production was mediated by another prostaglandin receptor. Possibly, PGF2α is binding to PGE2
receptors and increasing cAMP, which leads to an increase in P4. The ability of cumulus cells to
respond to hCG with an increased P4 indicates that, even after ovulation, hCG is capable of
signaling the oocyte. Human cumulus oocyte complexes express LH receptors (LHR) and upregulate LHR expression during the ovulatory process even though LHR expression in cumulus
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cells is much lower than in mural granulosal cells (Jeppesen et al., 2012).
It is commonly accepted that increases in intracellular Ca+2 in response to FP activation
cause a decrease in P4 production in luteal cells. A quadratic effect on P4 production was seen
when the calcium buffering capacity of the cells was increased by BAPTA. Increases in
intracellular Ca+2 were needed to support P4 production in bovine luteal cells (Alila et al., 1990).
Concentrations of BAPTA at 5 and 50 µmol were needed before a decrease in P4 production was
observed in experiment 4 (Figure 7). A threshold of intracellular Ca+2, even beyond the highest
concentration in experiment 4, may be needed to decrease P4 production. Lower concentrations
of BAPTA had either no effect or stimulated P4 production (Figure 7). This result supports a
biphasic role for Ca+2 in P4 production in human mural granulosal cells. By pharmacologically
increasing intracellular Ca+2 with an ionophore, A23187, basal P4 production was increased.
This is contradictory to the findings of Goravanahally et al. (2009), in which A23187 did not
affect basal P4 production in cultured bovine luteal cells. Differences between species or the
stage of luteinization could explain this difference. Luteinized granulosal cells and luteal cells
share several characteristics; however, they are not identical.
In summary, human mural granulosal cells can serve as a valuable model for
understanding how increases in intracellular Ca+2 and its downstream targets affect P4
production in steroidogenic cells. Additionally, P4 production by mural granulosal cells differed
among primary infertility type, age, BMI, and pregnancy outcome and may be used to study each
of these factors individually. Understanding similarities and differences between previously
mentioned factors has the potential to improve IVF protocols and to decrease the incidence of
luteal-insufficiency-induced miscarriages.

64

B
5	
  
4	
  

b

3	
  
2	
  

b

b

a

1	
  
0	
  
Control	
  

PG	
  

5	
  

Progesterone	
  (ng/ml)	
  

Progesterone	
  (ng/ml)	
  

A

hCG	
   PG	
  +	
  hCG	
  

4	
  
3	
  

a

a

a

a

2	
  
1	
  
0	
  
Control	
  

PG	
  

hCG	
   PG	
  +	
  hCG	
  

	
  

D
a

5	
  

a

4	
  
3	
  

Progesterone	
  (ng/ml)	
  

Progesterone	
  (ng/ml)	
  

C

	
  	
  

a
a

2	
  
1	
  
0	
  
Control	
  

PG	
  

hCG	
   PG	
  +	
  hCG	
  

	
  

5	
  
4	
  
a

3	
  
2	
  

a

a

a

1	
  
0	
  
Control	
  

PG	
  

hCG	
   PG	
  +	
  hCG	
  

	
  

Figure 3.1: Progesterone production by granulosal cells from patients with male factor (A),
endometriosis (B), diminished ovarian reserve (C), and tubal (D) primary infertility.
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Figure 3.2: Progesterone production in mural granulosal cells was affected by age. Cells from
patients who ranged in age from 25-30 (n=4) did not respond to hCG with a significant increase
in P4 production (A). However, cells from other age groups (31-35, n = 15 and 36-40, n = 6)
had significant increases in P4 when stimulated with hCG (ages 31-35 and ages 36-40 in B and
C, respectively).
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Figure 3.3: Progesterone production in mural granulosal cells was affected by BMI. Cells from
patients with (A) normal BMI (18.5-24.9, n = 16) had a significant increase in P4 production
when treated with hCG (P < 0.0001). Cells of patients who were categorized as (B) overweight
(BMI of 25-29.9, n = 6) or (C) obese (BMI >30, n = 3) did not have an increase in P4 production
when stimulated with hCG (P > 0.05)
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Figure 3.4: Progesterone production in mural granulosal cells was affected by pregnancy status
post IVF. Luteinized mural granulosal cells from patients who became pregnant (B) to the IVF
cycle produced significantly more P4 when stimulated with hCG than cells from those who did
not become pregnant (A) (3.23 vs. 1.57 ng/ml; P < 0.05).
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Figure 3.5: The AMPK activator, AICAR, inhibited P4 production by human luteinized mural
granulosal cells at all dosages tested (A). In B, the AMPK inhibitor, DM, did not affect basal P4
production.
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Figure 3.6: PGF2α stimulated P4 production in mural granulosal cells (A) but not in cumulus
granulosal cells (B). Adding a PG receptor antagonist, AL 8810, did not block stimulation in
mural cells and had no effect in cumulus cells (A). P4 production in cumulus cells was
stimulated by hCG, shown in B.
70

	
  
	
  
	
  
	
  

Ln (P4/C) = 0.2802551 + 0.0045803*Ln(BAPTA concentration+0.0001) - 0.0097173*(Ln(BAPTA
concentration+0.0001)--3.589)^2

Figure 3.7: BAPTA had a biphasic effect on P4 production in luteinized mural granulosal cells.
Data are presented as natural log of the ratio of BAPTA-treated to control values.
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Figure 3.8: Increases in intracellular calcium increased P4 production in mural granulosal cells.
A23187 increased P4 concentrations at 0.01, 0.1, and 1μmol concentrations (A, B, and C
respectively).
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